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ABSTRACT 
 
Introduction 
Invasive pneumococcal disease (IPD) is an important cause of morbidity and 
mortality in many parts of the world. It is estimated that pneumococcal disease 
causes more than one million-childhood deaths every year and the burden of disease 
is greater in developing countries. The main aim of this study was to analyze risk 
factors associated with mortality in invasive pneumococcal disease in all ages in 
South Africa.  
 
Materials and Methods 
We performed an analytical cross-sectional analysis of secondary data from 
national population-based surveillance for invasive Streptococcus pneumoniae 
infection in South Africa. The study period was 1 January 2003 to 31 December 
2005, and the mortality analysis used a subset of laboratory-confirmed cases who 
had a completed case report form and available mortality data. Multiple logistic 
regression models were constructed to identify risk factors significantly associated 
with the increased risk of death in patients with invasive pneumococcal disease. 
Separate models were used to evaluate risk factors for death in patients with 
meningitis and those with other IPD.  
 
Results 
There were 1154 (24%) cases of Streptococcus pneumoniae meningitis and 3736 
(76%) cases of other invasive disease. The overall case fatality rate was 1360/4890 
(27.8%) of which 911 (67%) patients died within 2 days of admission and 449 
(33%) died between 2 days and 30 days of admission. 
 
Variables associated with mortality in a logistic regression analysis of all IPD 
patients included meningitis (OR 2.8, CI 1.9 – 3.9, P=<0.001), HIV-infection (OR 
2.8, CI 1.6 – 4.6, P=<0.001), acute severe illness measured by Pitt bacteraemia 
score >=4 (OR 4.7, CI 2.8 – 7.7, P=<0.001) and prior antibiotic use within 2 months 
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before first positive culture (OR 2.1, CI 1.4 – 3.1, P=<0.001). In addition to this 
children less than 1 year and adults ≥45 years were more likely to die compared to 
other age groups. Patients from Western Cape Province were significantly less 
likely to die (OR 0.27, CI 0.15 – 0.50, P=<0.001) compared to other provinces.  
 
Amongst HIV-positive patients severe immunosuppression (low CD4+ count) was a 
risk factor for death. Risk factors for death were similar in patients with other IPD 
and meningitis except for HIV which was associated with death in the meningitis 
group but not in the other IPD group. Antibiotic resistance and vaccine-serotype 
disease were not associated with increased risk of death.  
 
Discussion and Conclusions 
IPD is associated with a high mortality in South Africa. Our findings of increased 
risk of death in HIV-positive patients especially those with low CD4+ count are of 
importance given the high prevalence of HIV amongst patients with IPD. 
Introduction of the pneumococcal conjugate vaccine as part of the national 
expanded program for immunization (EPI) and ensuring access to antiretroviral 
therapy for HIV-positive patients where indicated should be prioritized. 
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CHAPTER 1 
 
General Introduction 
This chapter gives an overview of the burden of invasive pneumococcal disease and 
why it is an important public health problem. The chapter also contains a statement 
of the problem, justification for the study, objectives of the study and a literature 
review from relevant publications. 
 
1.1 Background 
Invasive Streptococcus pneumoniae infection is an important cause of morbidity 
and mortality in many parts of the world.(1-4) The most common risk groups are 
children under 2 years, those older than 65 years and people with underlying 
immunodeficiency such as human immunodeficiency virus (HIV) infection.(1;2;5) 
HIV seroprevalence in South Africa is >20% in people of age 15-49 years which 
means that more people are prone to invasive S. pneumoniae infections.(4;6-8) 
Increasing resistance to antimicrobials is an additional concern.(4;6;7;9) 
 
The National Institute for Communicable Diseases (NICD) Respiratory and 
Meningeal Pathogens Research Unit (RMPRU) has been conducting national 
laboratory-based surveillance for invasive pneumococcal disease (IPD) in South 
Africa since 2000. Objectives of the surveillance system include obtaining a more 
precise national estimate of the burden of IPD, monitoring trends of emerging 
antibiotic resistance as well as monitoring the association between IPD and HIV 
infection in this population. Information is provided to clinicians and public health 
specialists for appropriate utilization.  
 
1.2 Statement of the problem 
HIV infection has compounded the already existing health burdens in many low and 
middle-income countries including South Africa.(1-4) Many studies have shown 
that HIV is a major risk factor for IPD, which has a high case fatality rate of up to 
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21.6% in those with underlying HIV.(1-4;7) Other studies have even reported death 
rates of 28% in patients with invasive pneumococcal pneumonia.(10) However HIV 
infection has not been shown to be a risk factor for mortality in patients with 
pneumococcal bacteraemia. To our knowledge there have been no studies 
evaluating HIV as a risk factor for mortality in patients with pneumococcal 
meningitis. 
 
Many studies have also shown increasing prevalence of paediatric 
serotypes/serogroups in the HIV-positive  adult population and these strains are 
commonly associated with penicillin resistance.(5-9) Penicillin resistance has not 
been shown to be associated with increased risk of mortality. Increasing levels of 
microbial resistance to penicillin, the first line treatment for pneumococcal disease, 
have been reported across the globe with occasional resistance to extended 
spectrum antibiotics i.e. cephalosporins.(11;12) 
 
South Africa has one of the highest reported rates of penicillin resistance and 
reported the first resistant isolates in 1977/8.(1;2) Due to selective pressure, 
additional classes of antibiotics in common use such as macrolides, cotrimoxazole 
and chloramphenicol may select resistance additional to penicillin resistance.(11) 
This scenario complicates control measures and clinical decision-making in the 
management of IPD in low and middle-income countries like South Africa, as 
alternative antibiotics like third-generation cephalosporins are expensive. 
 
Most of the commonly reported resistant serotypes are well covered by the 7-valent 
pneumococcal conjugate vaccine (PCV7),(13;14) which unfortunately is not 
accessible to many low and middle-income countries. Studies in United States of 
America (USA), Canada and Australia have shown a significant decline in the 
prevalence of penicillin resistance following vaccine introduction.(9;13;14) These 
studies have also shown a decline in the prevalence of IPD in both vaccinated and 
unvaccinated populations since the vaccine was introduced for widespread use. The 
indirect effect is thought to be due to herd immunity.(9;13;14) Whether penicillin 
 3 
resistance, vaccine-serotype disease and HIV infection are associated with mortality 
in patients with IPD has not been clearly demonstrated. 
 
1.3 Justification 
There have been no studies done to identify the risk factors for mortality due to IPD 
in South Africa on a national level. This data would be useful in planning targeted 
public health interventions to control IPD. 
 
1.4 Literature Review 
1.4.1 Overview of studies evaluating risk factors for pneumococcal mortality 
Pneumonia is the leading infectious cause of death in both children and adults. It is 
estimated that pneumococcal disease causes more than one million childhood 
deaths every year and the burden of disease is greater in developing countries.(2;15) 
Mortality from invasive pneumococcal disease ranges from 2.8% in uncomplicated 
cases to 58% in pneumococcal meningitis cases.(2;5;11;16;17) 
 
Previous studies have looked at risk factors associated with death in patients with 
pneumococcal bacteraemia. Rondon et al. in Madrid, Spain found that low white 
cell count less than 10,000/cubic mm; acidosis; respiratory symptoms or signs 
(tachypnoea, chest pain, wheezing); neurological findings (altered consciousness) 
were associated with death, but found no association between HIV infection, 
antibiotic resistance and death.(17) 
 
Feikin et al. observed that there was no increased mortality from bacteraemic 
pneumococcal pneumonia among patients with HIV infection.(18) Turett et al. in 
New York, USA found that severity of the illness (odds ratio [OR] 33.8, P<0.001); 
multilobar infiltrates and/or effusion (OR 2.4; P=<0.02); Hispanic ethnicity (0R 2.4, 
P=<0.02); age (P=<0.02) and high-level penicillin resistance (OR 6.0; P<0.02) were 
significantly associated with death.(16) This is the first study that reports penicillin 
resistance as an independent risk predictor of death among pneumococcal 
bacteraemia patients. In Johannesburg, South Africa, Feldman et al. also showed 
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severity of illness as a predictor of mortality in bacteraemic pneumococcal 
pneumonia.(3) 
 
We evaluated whether pneumococcal resistance to penicillin, HIV infection and 
childhood pneumococcal serotypes/serogroups were associated with increased 
mortality among patients with invasive pneumococcal disease. These data may 
contribute to our understanding of how universal vaccination for pneumococcus 
would impact on disease in South Africa. 
 
1.4.2 Childhood Serotypes/Serogroups 
Childhood S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, 23F are a major cause 
of IPD in children and are normally carried in the nasopharynx of young children. 
This makes daycare centers, orphanages etc conducive environments for 
transmission of S. pneumoniae among children, at the same time exposes adult 
caretakers to the risk of acquiring infection. It has been shown that there is an 
increase in the prevalence of IPD in adults caused by childhood serotypes(1;2) and 
the frequency of occurrence was more in women compared to men (47% vs. 21%, 
P=0.01).(3;6) 
 
Pneumococcal conjugate vaccine has been shown to be effective in reducing 
pneumococcal carriage. The efficacy of this vaccine (PCV7) in reducing IPD 
burden has been shown by studies done in USA, Canada, Australia, Western Europe 
and other parts of the world.(13;14;19;20) Even though the burden of invasive 
disease is increasing due to childhood serotypes, no study to date has looked at the 
impact of childhood serotypes on mortality in patients with IPD in South Africa. 
 
1.4.3 HIV Infection 
HIV infection has been shown to be a major risk factor for IPD in Africa and other 
parts of the world. In South Africa increasing prevalence of HIV has had an impact 
on occurrence of IPD with more cases occurring in HIV-seropositive individuals as 
compared to HIV-seronegative individuals.(1;2) Madhi et al. found that among 
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children the overall burden of IPD was 41.7 times higher (confidence interval (CI) 
26.5-65.6) in HIV-infected compared with HIV-uninfected children.(8) Similar 
findings were also shown by Jones et al who reported a 36.9 fold increase in IPD 
among HIV-seropositive compared to HIV-seronegative children and 8.2 fold 
increase in IPD among HIV-seropositive adults compared to HIV-seronegative 
adults.(4) 
 
Crewe-Brown et al. demonstrated a significant difference in the proportion of 
paediatric serotypes among the HIV-seropositive compared to HIV-seronegative 
patients with IPD (37.0% vs. 25.4%) (OR 1.73, CI 0.98-3.05, P=0.04).(7) HIV-
seroprevalence could therefore explain why childhood serotypes are commonly 
causing IPD in adults. However HIV infection has not been clearly shown to be a 
risk factor for death in patients with IPD.(2-4;8;10;16) 
 
1.4.4 Penicillin Resistance 
Penicillin resistance has been increasing at an alarming rate partly because of 
injudicious use of antibiotics. The highest reported rates of resistance in South 
Africa have been 39.4% among cases of IPD in a study done in 1996/97. In that 
study penicillin non-susceptible isolates increased from 35.5% as observed in 
1986/87.(1;16) 
 
Antimicrobial resistance in the pneumococcus has been shown to be higher in 
children compared to adults.(6;7) and that women compared to men harbor more 
penicillin non-susceptible isolates (15% versus 1%, P=0.008) including 
cotrimoxazole resistant isolates (21% versus 5%, P=0.016).(3) Childhood 
serotypes/serogroups have been associated with penicillin resistance and also 
resistance to other antibiotics.(6) Since childhood serotypes occur more in women 
than men, this could be the reason why women harbor more penicillin non-
susceptible isolates than men.(8) 
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An association between antibiotic resistance and HIV seropositivity was shown 
among adult patients: 19% of isolates in the HIV-positive patients were penicillin 
resistant compared to 4.25% in the HIV-negative patients (OR 5.25, CI 2.25-12.45, 
P=<0.001).(7) This association was more significant in children where 53.3% of the 
isolates in HIV- positive and 30.2% of the isolates in HIV- negative patients were 
resistant to penicillin.(7) However many previous reports have not documented 
increased mortality in patients with penicillin-resistant isolates.(1-8;10;16) 
 
One study in the USA that reported an association with mortality has been 
highlighted above.(16) Therefore
 
data are lacking on risk factors for mortality due 
to invasive pneumococcal disease at national level. This study was therefore 
undertaken to determine risk factors for mortality in patients with invasive 
pneumococcal disease in South Africa. 
 
1.5 Objectives 
1. To describe risk factors for mortality in the population of laboratory-confirmed 
invasive pneumococcal disease patients of all age groups in South Africa. 
Specific exposures of interest included: 
• Antibiotic susceptibility and non-susceptibility to penicillin.  
• Vaccine type and non-vaccine type disease.  
• HIV-seropositive and HIV-seronegative patients. 
• Meningitis and other invasive pneumococcal disease.  
 
2. To determine risk factors for death in patients with meningitis and those with 
other IPD 
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CHAPTER 2 
 
Materials and Methods 
In this chapter study population, data sources and data management are discussed. 
Definitions of variables, study hypotheses as well as statistical methods and data 
analyses are stated. 
 
2.1 Study Design  
This was an analytical cross-sectional analysis of secondary data from national, 
population-based surveillance for IPD in South Africa. The study period was 1 
January 2003 to 31 December 2005 and data were collected from eight of the nine 
provinces. The analysis used a subset of the surveillance data from enhanced 
surveillance sites with completed case report forms (CRFs) and data on outcome. 
 
2.2 Hypothesis 
We hypothesized that age of the patient, HIV infection, vaccine-serotype disease 
and penicillin resistance were independent risk factors for mortality in patients with 
IPD in South Africa and that risk factors might differ for meningitis and other IPD. 
 
2.3. Surveillance for Invasive Pneumococcal Infection. 
The Respiratory and Meningeal Pathogens Research Unit (RMPRU) of the NICD 
performed laboratory-based surveillance for invasive pneumococcal infections. The 
surveillance system defined invasive infection as isolation of pneumococcus from a 
normally sterile site (e.g. blood, CSF, peritoneal fluid, pleural fluid and joint fluid). 
All clinical laboratories in South Africa were encouraged to send isolates of 
pneumococci to the RMPRU reference laboratory. Here culture, antimicrobial 
susceptibility testing and serotyping were done on each isolate that had been 
received.(21;22) 
 
The surveillance system established enhanced sites in 8 of the 9 provinces in order 
to obtain more detailed epidemiologic data on patients from those sites. Gauteng 
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and KwaZulu Natal Provinces had 4 sites each, Mpumalanga and Western Cape had 
3 sites each, Limpopo and Free State had 2 sites each, and Eastern Cape and North 
West had 1 site each (Appendix 1). In addition to laboratory reinforcement, 
surveillance officers who were qualified nurses were placed at each of these 
hospitals to collect data from cases admitted to these hospitals with a laboratory 
diagnosis of invasive pneumococcal disease. Using standardized case report forms 
(Appendix 3); they collected data on demographic, clinical and microbiologic 
characteristics as well as clinical outcomes on each case. These data were abstracted 
from hospital records and through interview with individual patients or their proxy. 
 
For patients without HIV test result, the surveillance officers carried out a pre-test 
and post-test counseling and document HIV test results in the case report forms. 
Therefore, data from enhanced sites were more complete on outcome since the 
surveillance officers follow up these patients from admission to outcome. Our study 
focused on a subset of the data from enhanced surveillance sites in order to examine 
risk factors for mortality. 
 
2.4 Study Population and sampling 
This 3-year study included records of all cases of invasive pneumococcal disease 
from enhanced surveillance sites reported to NICD. The mortality analysis was 
restricted to a subset of laboratory-confirmed IPD cases i.e. those who had a 
completed CRF with available mortality data. 
 
Preliminary analysis was done to compare patients included in the mortality risk 
factor analysis to the overall IPD population to ascertain comparability of the two 
groups. Additional separate analyses were done to evaluate risk factors for death in 
the population of cases with confirmed meningitis and those with other IPD. 
Another separate analysis was done to assess the influence of low CD4+ count on 
mortality in a population of IPD patients with HIV co-infection.  
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2.5 Data management  
The pneumococcal surveillance data for 2003-2005 were entered in EPI info 
Version 6.04d computer software package (Centers for Disease Control and 
Prevention, Atlanta, Georgia) by a team of data entry clerks at RMPRU and 
exported into a Microsoft Excel spreadsheet workbook. Validity of the data was 
done by checking the database for completeness of the records and identification of 
errors on data entry. This was done by verifying approximately 10% of the records 
in the database with records as they appeared on the case report forms. Mostly 
demographic and clinical data were verified. This helped to assess consistency of 
records entered with data on case report forms.(23) Identified errors were corrected 
on the database. 
 
Inconsistent laboratory data for CD4+ count and viral load was also verified using 
the computerised laboratory database. All variables of interest were then recoded 
for analysis such that most variables then became dichotomous. Cross tabulations 
and frequency tables were done to ascertain internal consistency of the data. 
Missing data were excluded from the analysis. Most of these validity checks were 
done using Excel software package and data were thereafter exported into Stata 
software, version 9.0 for analysis.  
 
2.6 Definitions 
All definitions of study variables were established before data were analyzed. 
 
2.6.1 Main exposures of interest 
• Invasive pneumococcal disease was defined as presence of a pneumococcal 
isolate from a normally sterile site, such as blood, cerebrospinal fluid (CSF), 
pleural fluid, peritoneal fluid and joint fluid in a patient admitted to 
hospital.(18) 
•  IPD clinical syndrome was defined as (i) Meningitis: isolation of 
pneumococcus from CSF. (ii) Bacteraemia: isolation of pneumococcus from 
blood (pneumonia and bacteraemia without focus). (iii) Other invasive 
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disease: isolation of pneumococcus from other sterile sites i.e. joint aspirate, 
peritoneal fluid and pleural fluid.  
• Age at last birthday in complete years on the day specimen was collected.  
• Vaccine-serotype disease was defined as IPD caused by pneumococcal 
serotypes found in the 7-valent pneumococcal conjugate vaccine. These are 
serotype/serogroup 4, 6B, 9V, 14, 18C, 19F and 23F.(13) 
• Antibiotic susceptibility for penicillin was defined as ‘non-susceptible’ 
referring to intermediate resistance or resistance (MIC>0.06 µg/ml) and 
‘susceptible’ referring to antibiotic susceptibility (MIC≤0.06 µg/ml).(24) All 
antibiotics were evaluated (penicillin, ceftriaxone, erythromycin, 
cotrimoxazole, clindamycin, chloramphenicol and rifampicin) but penicillin 
was the main exposure because it is the main drug of choice. 
• HIV status was defined as presence of a positive or negative ELISA test 
(enzyme-linked immunosorbent assay) result.(6) 
 
2.6.2 Other exposures evaluated 
• Nosocomial infection was defined as invasive pneumococcal disease 
occurring more than 2 days after the patient was admitted to hospital. 
• Acute severe illness was defined as a Pitt bacteraemia score equal to or 
greater than 4 at the time of the positive blood/CSF. This score is used to 
measure severity of disease in bacteraemia but was used in meningitis 
patients as a measure of generalized sepsis  
The Pitt bacteraemia score was assessed using the following parameters: 
(i) Oral temperature: 2 points for a temperature of ≤35ºC or ≥40ºC, 1 
point for temperature of 35.1ºC-36.0ºC or 39.0ºC–39.9ºC and 0 
point for temperature of 36.1ºC-38.9ºC. 
(ii)  Hypotension: 2 points for systolic blood pressure of less than 90 
mm Hg.  
(iii) 2 points for receipt of mechanical ventilation  
(iv) 4 points for cardiac arrest  
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(v) Mental status: if alert 0 point; disoriented 1 point; stuporous 2 points 
and comatose 4 points.(25;26)  
 
• Underlying illness associated with immunosuppression was defined as the 
presence of malignancy, asplenia, autoimmune condition, organ transplant 
or receipt of immunosuppressive agents e.g. prednisolone or other cytotoxic 
drugs. Other underlying medical condition were defined as presence of 
tuberculosis, diabetes mellitus, cirrhosis / liver failure, chronic renal failure, 
heart disease, asthma, malnutrition, severe burns, severe trauma and head 
injury.(27) 
• Prior antibiotic use within 24 hours was defined as use of any antibiotic less 
than or equal to 24 hours before the first positive blood/CSF culture.(25-27) 
• Prior antibiotics use within the past 2 months was defined as use of any 
antibiotic other than cotrimoxazole prophylaxis within the 2 months 
preceding the first positive blood/CSF culture.(25-27) 
• Cotrimoxazole prophylaxis was defined as regular use of cotrimoxazole for 
purposes of Pneumocystis jiroveci pneumonia prophylaxis in HIV-sero 
positive patients. 
• Low CD4+ count was defined as CD4+ absolute value indicative of severe 
immune deficiency in HIV co-infection as shown below (Table 2.1). 
 
Table 2.1: CD4 + criteria for severe HIV immunodeficiency 
  
Immunological 
markers 
Age-specific recommendation to initiate ART
a
 
 ≤11 months 12-35months 36-59months ≥5years 
%CD4+
b
 <25% <20% <15% <15% 
CD4 count
b
 <1500cells/mm
3
 <750 cells/mm
3
 <350cells/mm
3
 <200cells/mm
3
 
 
a
 Cut off levels for initiating antiretroviral therapy (ART). CD4+ drop below these 
levels significantly increases the risk of disease progression and death. 
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b 
CD4+% is the preferred measure for children <5 years old. 
(The table has been adapted from ‘Antiretroviral therapy of HIV infection in infants 
and children in resource-limited settings: towards universal access’, WHO 
2006.(28)) 
 
• Gender was defined as either male or female sex.  
• Alcohol abuse was defined as self report of alcohol abuse or not. 
• Smoking status was defined as “current smoker” or “does not smoke”. 
• Province was defined as one of the nine provinces in South Africa in which 
the patient presented to hospital. 
• Race was defined as black, coloured, white or Indian origin. 
 
2.6.3. Outcome  
The outcome of interest was mortality defined as death within 30 days of admission 
after the first positive blood/CSF culture result for S pneumoniae was obtained. 
Patients who were discharged from hospital within or after 30 days were considered 
to have survived the episode. To minimize misclassification of deaths that may have 
occurred due to causes other than pneumococcal infection, all deaths occurring after 
30 days were excluded from the analysis. Those with missing data on outcome and 
date of death were also excluded.(18) 
 
2.7 Laboratory methods  
2.7.1 Antibiotic susceptibility testing 
Susceptibility testing for penicillin, rifampicin, trimethoprim/sulphamethoxazole, 
erythromycin, clindamycin, chloramphenicol and tetracycline was determined by 
the disk diffusion method.(24) Minimum inhibitory concentrations (MIC) were 
confirmed by agar dilution for penicillin and ceftriaxone, and by Etest (AB Biodisk, 
Solna, Sweden) for all the other antimicrobials. CLSI breakpoints for meningitis 
were used for ceftriaxone. For penicillin the term ‘non-susceptible’ referred to 
intermediate resistance or resistance (MIC>0.06 µg/ml) and the term ‘susceptible’ 
referred to antibiotic susceptibility when MIC≤0.06 µg/ml. For all other antibiotics, 
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isolates were categorised as “non-susceptible” referring to intermediate resistance 
and resistance, or “susceptible”, according to Clinical and Laboratory Standards 
Institute (CLSI) guidelines (24). 
 
2.7.2 Pneumococcal Serotyping  
All pneumococcal isolates were serotyped by capsular swelling (Quellung reaction) 
using sera from the Staaten Serum Institute (SSI), Copenhagen, Denmark. 
 
2.7.3 HIV testing 
This was done by using enzyme-linked immunosorbent assay (ELISA). A positive 
HIV test result referred to a positive serum reaction to ELISA test.(6) Two HIV 
ELISA tests were used: Determine HIV-1/2 (Abbott GmbH) and Murex HIV 1+2 
(Murex Diagnostic Limited). 
 
2.8 Statistical methods and Data analysis 
Statistical analysis was done using Stata statistical software, version 9.0 (Stata 
Corp.2005. College Station, Texas). The chi-squared test was used to compare 
differences in characteristics between categorical variables (e.g. demographic and 
microbiologic characteristics of cases from enhanced surveillance and non 
enhanced surveillance sites). Continuous variables (e.g. age, CD4+ count) were 
compared using Mann-Whitney U-test. Factors that were significant at P≤0.1 on 
univariate analysis were included in logistic regression models to assess the effects 
of multiple risk factors on invasive pneumococcal disease mortality. 
 
Stepwise logistic regression employing forward selection and backward 
elimination.The models were also tested for goodness of fit using the Pearson X
2 
and the deviance X
2
. Interactions between main effects in the models were also 
assessed for significance and co linearity. Potential confounding variables were 
adjusted for in the models. Precision of estimate for odds ratio in the logistic 
regression models was defined as P≤0.05 significance level. All statistical tests 
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excluded missing values. In this study P>0.05 in the multivariate analysis was 
considered not statistically significant. 
 
Incidence rates were calculated based on the number of cases reported each year 
from January 1 through December 31, divided by mid-year population estimates for 
each year supplied by Statistics South Africa (Stats SA). The incidence rates were 
calculated from all IPD cases reported by age and province. 
 
Preliminary analyses were conducted to compare patients from enhanced 
surveillance sites (those eligible to have CRFs completed and be included in the 
mortality analysis) to the population of all patients with IPD. This was done 
because if patients from enhanced surveillance sites were very different from 
patients at non-enhanced sites this might affect generalizability of findings. 
Amongst patients presenting to enhanced surveillance sites those who had 
completed case report forms were compared to those without case report forms. 
Only patients with completed CRFs were included in the mortality analysis as 
mortality data was unreliable in those without CRFs. 
 
Descriptive analysis was performed for patients with completed CRFs (i.e those 
included in the mortality analysis). For some of the main exposures of interest (e.g. 
HIV infection, meningitis versus other IPD and antibiotics in the last 2 month), 
exposed and unexposed groups were compared to better characterize these groups. 
 
For the analysis of risk factors for mortality multiple models were constructed:  
(i) ‘The all IPD model’ to evaluate risk factors for death in all IPD patients.  
(ii) Separate models for meningitis and other IPD to investigate if risk factors 
associated with mortality were different between the two clinical syndromes.  
(iii) The low CD4+ count model to evaluate if low CD4+ was a risk factor for death 
in IPD patients with HIV co-infection. 
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2.9 Ethical approval 
The Postgraduate Committee and the Research Ethics Committee, Faculty of Health 
Sciences, University of Witwatersrand approved the study. 
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CHAPTER 3 
 
Results 
 
3.1 Overview of all IPD cases 
There were 11,116 cases of IPD reported to RMPRU from 2003 to 2005.  
 
3.2 Incidence rates of IPD 
The national incidence rates of IPD were 7/100,000 for 2003, 8.2/100,000 for 2004 
and 8.8/100,000 for 2005.There was an increasing trend of IPD over the study 
period. 
The incidence rates were highest in children <1 year 49.9/100,000 persons in 2003, 
63.1/100,000 persons in 2004 and 66.9/100,000 in 2005 and lowest in the young 
adults 15- 24 years 2.1/100,000 2003, 2.7/100,000 2004 and 2.2/100,000 for 2005. 
The burden of IPD was highest in Gauteng, Western Cape and Mpumalanga 
provinces, which also showed an increasing incidence rates over the study period 
(Figure 1 and Figure 2). 
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Figure 1: Age-specific annual incidence rates of invasive pneumococcal disease in 
South Africa by year, 2003-2005. 
 
 
 18 
0
5
10
15
20
25
30
Ea
st
er
n 
C
ap
e
Fr
ee
 S
ta
te
G
au
te
ng
K
w
aZ
ul
u 
N
at
al
Li
m
po
po
M
pu
m
al
an
ga
N
or
th
er
n 
Ca
pe
N
or
th
 W
es
t
W
es
te
rn
 C
ap
e
Province
C
a
se
s/
1
0
0
,0
0
0
 p
o
p
u
la
ti
o
n
2003
2004
2005
 
Figure 2: Annual incidence rates of invasive pneumococcal disease by province and 
year, 2003-2005. 
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3.3 Comparison of population included in mortality study to population of all 
IPD in South Africa 
 
3.3.1 Comparison of cases presenting to enhanced and non-enhanced sites 
(Table 3.1). 
6302 (56.7%) cases were reported from Gauteng Province followed by 1430 
(12.9%) from Western Cape Province and 1216 (10.9%) from KwaZulu Natal 
Province. Northern Cape Province reported the lowest number of cases 73 (0.7%). 
Of the total number of cases, 6051 (54%) were from enhanced sites and 5065 (46%) 
were from non- enhanced sites. 
 
There was slightly more missing data on age at non-enhanced sites (7.6% versus 
4.0%). There were significant differences in the age distribution of cases from 
enhanced and non-enhanced sites. In the enhanced sites the burden of disease was 
higher in the <1 year age group 1086 (18%), the 1-4 years age group 1002 (16.6%) 
and the 25-44 years age group 2035 (33.6%). Distribution of cases at the non-
enhanced sites showed a similar pattern with the burden being higher in the <1 year 
old group 764 (15.1%), the 1-4 years 758 (15.0%) and 25-44 years 1660 (32.8%). 
However enhanced sites reported a greater proportion of cases in these age groups 
compared to non-enhanced sites and this observed difference was significant 
(P=0.006). Gender distribution between enhanced and non-enhanced sites was not 
different, but there were more missing data on gender from non-enhanced sites. 
 
Of the cases reported from enhanced sites within the study period 3422 (56.6%) 
were from Gauteng Province, 842 (14%) were from Western Cape Province, 934 
(15.4%) were from KwaZulu Natal Province and 377 (6.2%) from Free State. There 
was a significant difference in proportion of cases reported between provinces 
comparing enhanced and non-enhanced sites (P=<0.001). There was a significant 
difference (P=<0.001) in the type of specimen collected between enhanced and non-
enhanced sites with more blood cultures in enhanced sites: 4333 (71.6%) compared 
to 2866 (56.6%) in the non-enhanced sites. There was a greater proportion of CSFs 
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at non-enhanced sites: 1945 (38.4%) compared to 1418 (23.3%) in enhanced sites. 
The proportions of vaccine and non-vaccine-serotypes between enhanced and non-
enhanced sites were not different (P=0.066). 
 
The proportions of antibiotic resistance were greater in enhanced sites as compared 
to non-enhanced sites: penicillin (28.4% versus 26.5% P=0.03), rifampicin (5% 
versus 3.5% P=<0.001) and cotrimoxazole (57.9% versus 51.9% P=<0.001).  
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Tables 3.1: Demographic and Microbiologic Characteristics of patients with 
invasive pneumococcal disease from enhanced and non-enhanced sites 
 
 Enhanced sites 
(n=6051)
 
Non-enhanced sites 
(n=5065) 
 
Characteristics N (%) N (%) *X
2
      P 
Age group in years 
<1 
1-4 
5-14 
15-24 
25-44 
45-64  
≥65 
Missing 
 
1086 (18.0) 
1002 (16.6) 
557 (9.2) 
351 (5.8) 
2035 (33.6) 
621 (10.3 
152 (2.5) 
247 (4.0) 
 
764 (15.1) 
758 (15.0) 
495 (9.8) 
310 (6.1) 
1660 (32.8) 
553 (10.9) 
139 (2.7) 
386 (7.6) 
 
 
18.1 
 
 
 
 
0.006 
Sex 
Male 
Female 
Missing 
 
3038 (50.2) 
2953 (48.8) 
60 (1.0) 
 
2497 (49.3) 
2437 (48.1) 
131 (2.6) 
 
0.011 
 
0.916 
Collection year 
2003 
2004 
2005 
 
1,787 (29.5) 
2,064 (34.1) 
2,200 (36.4) 
 
1,439 (28.4) 
1,719 (33.9) 
1,907 (37.7) 
 
 
2.47 
 
 
0.291 
Serotypes 
Vaccine 
Non-vaccine 
Missing 
 
2,129 (35.2) 
3,209 (53.0) 
713 (11.8) 
 
1,784 (35.2) 
2,900 (57.3) 
381 (7.5) 
 
3.384 
 
0.066 
Province 
Gauteng 
Eastern Cape 
Western Cape 
Mpumalanga 
KwaZulu Natal 
North West 
Free State 
Limpopo 
Northern Cape 
 
3,422(56.6) 
178(2.9) 
842(14.0) 
189(3.1) 
934(15.4) 
20 (0.3) 
377(6.2) 
89(1.5) 
0(0.0) 
 
2,880(56.8) 
292(5.8) 
588(11.6) 
348(6.9) 
282(5.6) 
348(6.9) 
158(3.1) 
96(1.9) 
73(1.4) 
 
 
 
 
891 
 
 
 
 
<0.001 
 
 
 
 
 
Specimen Site 
CSF 
Blood 
Other† 
 
1,418 (23.4) 
4,333 (71.6) 
300 (5.0) 
 
1,945 (38.4) 
2,866 (56.6) 
254 (5.0) 
 
 
300 
 
 
<0.001 
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Penicillin NonS# 
No 
Yes 
 
3823 (71.6) 
1516 (28.4) 
 
3443 (73.5) 
1241 (26.5) 
 
4.52 
 
0.03 
Ceftriaxone NonS 
No 
Yes 
 
5294 (99.2) 
45 (0.8) 
 
4646 (99.2) 
38 (0.8 
 
0.03 
 
 
0.86 
 
Rifampicin NonS 
No 
Yes 
 
5072 (95.0) 
267 (5.0) 
 
4520 (96.5) 
164  (3.5) 
 
13.64 
 
 
<0.001 
 
Cotrimoxazole 
NonS 
No 
Yes 
 
2249 (42.1) 
3090 (57.9) 
 
2252 (48.1) 
2432 (51.9) 
 
35.76 
 
 
<0.001 
 
Erythromycin NonS 
No 
Yes 
 
4624 (86.6) 
715 (13.4) 
 
4057(86.6) 
627 (13.4) 
 
0.001 
 
 
0.99 
 
Clindamycin NonS 
No 
Yes 
 
4809 (90.1) 
530 (9.9) 
 
4209 (89.9) 
475 (10.1) 
 
0.13 
 
 
0.72 
 
Chloramphenicol 
NonS 
No 
Yes 
 
5192(97.2) 
147(2.8) 
 
4543 (97) 
141(3.0) 
 
0.59 
 
0.44 
Missing†† 
 
713 (11.8) 381 (7.5)   
 
*Missing values not included in chi squared test 
†† Missing data for antibiotic susceptibility testing. 
# NonS: Streptococcus pneumoniae isolates not susceptible to the mentioned 
antibiotics. 
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3.3.2 Comparison of cases from enhanced sites with and without case report 
forms (Table 3.2). 
Of the 6051 cases from enhanced sites 4961(82%) had case report forms and 
1090(18%) had no case report forms. Generally there was more missing data in 
cases without case report forms. The distribution of cases with and without CRFs 
differed by province (P=<0.001). There was also a significant difference in the type 
of specimens taken between cases with case report forms and those without case 
report forms, showing higher proportions in blood culture (23.9%) and CSF 
(71.8%) among cases with case report forms compared to those without case report 
forms, blood culture (21.3%) and CSF (70.6%) (P=<0.001). No differences were 
noted in antibiotic resistance between cases with and without case report forms.  
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Table 3.2: Demographic and Microbiologic Characteristics of patients with 
invasive pneumococcal disease from enhanced sites with and without Case 
Report Forms 
 
 Case Report Forms 
(n=4961)
 
No Case Report Forms 
(n=1090) 
 
Characteristic N (%) N (%) *X
2
 P 
Age group in years 
<1 
1-4 
5-14 
15-24 
25-44 
45-64 
=>65 
Missing 
 
940/ (19.0) 
860 (17.3) 
473 (9.5) 
310 (6.2) 
1,716(34.6) 
521 (10.5) 
133 (2.7) 
8 (0.2) 
 
146 (13.4) 
142 (13.0) 
84 (7.7) 
41 (3.8) 
319 (29.3) 
100 (9.2) 
19 (1.7) 
239 (21.9) 
 
 
 
 
7.3 
 
 
 
 
0.292 
 
 
 
Sex 
Male 
Female 
Missing 
 
2516 (50.7) 
2440 (49.2) 
5 (0.1) 
 
522 (47.9) 
513 (47.1) 
55  (5.1) 
 
0.038 
 
0.846 
 
 
Collection Year 
2003 
2004 
2005 
 
1387 (27.9) 
1782 (35.9) 
1792 (36.1) 
 
400 (36.7) 
282 (25.9) 
408 (37.4) 
 
 
50.0 
 
 
<0.001 
Serotypes 
Vaccine 
Non-vaccine 
Missing 
 
1745(35.2) 
2640 (53.2) 
575 (11.6) 
 
384 (35.2) 
569 (52.2) 
137 (12.6) 
 
0.0813 
 
0.766 
Province** 
Gauteng 
Eastern Cape 
Western Cape 
Mpumalanga 
KwaZulu Natal 
North West 
Free State 
Limpopo 
 
2,742 (55.3) 
167 (3.4) 
794(16.0) 
162 (3.3) 
629 (12.7) 
13 (0.3) 
366 (7.4) 
88 (1.8) 
 
680 (62.4) 
11(1.0) 
48 (4.4) 
27 (2.5) 
30 (28.0) 
7 (0.6.) 
11(1.0) 
1 (0.1) 
 
328 
 
<0.001 
 
 
 
 
 
Specimen Site 
CSF 
Blood 
Other† 
 
1186 (23.9) 
3563 (71.8) 
212 (4.3) 
 
232 (21.3) 
770 (70.6) 
88 (8.1) 
 
29 
 
<0.001 
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Penicillin NonS# 
No 
Yes 
 
3139 (71.6) 
1247 (28.4) 
 
684 (71.8) 
269 (28.2) 
 
0.016 
 
0.899 
Ceftriaxone NonS 
No 
Yes 
 
4354 (99.3) 
32 (0.7) 
 
940 (98.6) 
13 (1.4) 
 
3.77 
 
 
0.052 
 
Rifampicin NonS 
No 
Yes 
 
4171 (95.0) 
215 (5.0) 
 
901 (94.5) 
52  (5.5) 
 
0.507 
 
 
0.477 
 
Cotrimoxazole NonS 
No 
Yes 
 
1831 (41.8) 
2555 (58.3) 
 
418 (43.9) 
535 (56.1) 
 
1.44 
 
 
0.23 
 
Erythromycin NonS 
No 
Yes 
 
3807 (86.8) 
579 (13.2) 
 
817 (85.7) 
136 (14.3) 
 
0.772 
 
 
0.38 
 
Clindamycin NonS 
No 
Yes 
 
3965(90.4) 
421(9.6) 
 
844(88.6) 
109(11.4) 
 
2.96 
 
 
0.085 
 
Chloramphenicol NonS 
No 
Yes 
 
4272(97.4) 
114(2.6) 
 
920 (96.5) 
33  (3.5) 
 
2.18 
 
0.140 
 
Missing†† 
 
575 (11.6) 
 
137 (12.6) 
  
 
 
*Missing values not included in chi squared test 
** Northern Cape not included, as it had no enhanced sites. 
†Other specimens include joint fluid, peritoneal fluid and pleural fluid. 
†† Missing data for antibiotic susceptibility testing. 
# NonS: Streptococcus pneumoniae isolates not susceptible to the mentioned 
antibiotics. 
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3.4 Description of cases included in analysis of risk factors for mortality 
Of 4,961 cases with completed case report forms, 4,890 had complete data on 
outcome within 30 days of admission. A total of 71 cases were excluded: 38 cases 
with missing data on outcome; 30 observations died after 30 days and 3 
observations had missing date of death. 
 
There were 1154 (24%) cases of Streptococcus pneumoniae meningitis and 3736 
(76%) cases of other invasive disease. 2958 (80%) of those classified as other 
invasive disease had bacteraemic pneumonia, 10% had bacteraemia without focus 
and a further 2% had pneumococcal isolates from other sterile sites (joint or 
peritoneal fluid).  
 
3.5 Underlying illness 
Of the 4890 patients included in the study 1236 had underlying disease, of these, 73 
(5.9%) had diabetes mellitus, 40 (3.2%) had coronary artery disease, 28 (2.3%) had 
valvular heart disease, 259 (21%) had malnutrition, 52 (4.2%) had liver disease, 94 
(7.6%) had renal disease, 51 (4.1%) had cancer, 84 (6.8%) had chronic obstructive 
airways disease, 38 (3.1%) had cerebral vascular accidents and 11 (0.9%) had 
burns. 
 
3.6 Antibiotics used during admission. 
Data for antibiotic use during admission were only available for year 2005, on 94 % 
(391/418) of the meningitis patients and 94% (1267/1349) of patients with other 
invasive disease. 
 
3.6 1 Antibiotics used for treating meningitis 
Among 391 patients with meningitis, 297 (76%) received a 3
rd
 generation 
cephalosporin, 1 (0.3%) received a 4
th
 generation cephalosporin, 81 (21%) received 
penicillin, 5 (1.3%) received a 1
st
 or 2
nd
 generation cephalosporin, and 7 (1.4%) 
received a combination of other drugs including chloramphenicol and augmentin.  
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3.6.2 Antibiotics used for treating patients with other invasive disease  
Among 1267 patients with other invasive disease, 265 (21%) received a 3
rd
 
generation cephalosporin, 1 (0.1) received a 4
th
 generation cephalosporin, 158 
(12.5%) received a 1
st
 or 2
nd
 generation cephalosporin, 552 (44%) received 
penicillin, 225 (18%) received augmentin and 66 (4.4%) received a combination of 
other drugs including ciprofloxacin, cotrimoxazole, gentamicin and erythromycin.  
 
3.7 Prior antibiotic use: 
Among 575 patients who received antibiotics 2 months prior to admission with an 
episode of invasive pneumococcal disease, 66% received penicillin, 16% received a 
cephalosporin and the 18% received a combination of other antibiotics, which 
included ciprofloxacin, erythromycin, gentamicin and cotrimoxazole 
 
3.8 Comparison of characteristics of cases of meningitis versus other invasive 
disease  
3.8.1 Demographic characteristics (Table 3.3). 
Age distribution of cases was significantly different between meningitis cases and 
other IPD (P=<0.001). Of those with meningitis 26% were children <1 year, 12% 
were children between 1 and 4 years, 13 % were children between 5 and 14 years, 
32% were adults between 25 and 44 years and 0.8% were those older than 64 years.  
 
Of those with other invasive disease 17% were children <1 year, 19% were children 
between 1 and 4 years, 9% were children between 5 and 14 years, 35% were adults 
between 25 and 44 years, 11% were adults between 45 and 64 years and 3% were 
those older than 64 years. Therefore meningitis was more common in the younger 
age groups whereas other invasive disease was more common in older adults. 
 
There was also a significant difference in racial distribution; a higher proportion of 
black patients presented with meningitis whereas a higher proportion of coloured 
patients presented with other invasive disease. There was also a significant 
difference in the distribution of meningitis and other invasive disease by province 
with more meningitis reported from Eastern Cape (8.2%), Mpumalanga (8.3%) and 
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Free State (9.3%) and more cases of other invasive disease reported from Gauteng 
(58%) and Western Cape (17.8%). These differences were statistically significant 
(P=<0.001).  
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Table 3.3: Comparison of demographic characteristics of patients with 
meningitis versus other invasive pneumococcal disease amongst patients’ from 
enhanced sites with case report forms. 
 
  
Meningitis 
 
Other invasive disease 
 
 
Characteristic N (%) N (%) X
2
 P 
Age group in years
 
<1 
1-4 
5-14 
15-24 
25-44 
45-64 
=>65 
 
296/1152 (25.7) 
138/1152  (11.9) 
144/1152  (12.5) 
94/1152  (8.2) 
370/1152  (32.1) 
101/1152  (8.8) 
9 /1152 (0.8) 
 
625/3730 (16.7) 
711/3730  (19.0) 
323/3730  (8.7) 
213/3730  (5.7) 
1323/3730  (35.5) 
413/3730  (11.1) 
122/3730  (3.3) 
 
 
112 
 
 
 
 
<0.001 
 
 
 
 
 
Sex
 
Male 
Female 
 
589/1153 (51.0) 
564/1153 (49.0) 
 
1892/3732 (50.7) 
1840/3732 (49.3) 
 
0.05 
 
0.818 
Race
 
Black 
White 
Asian 
Coloured 
 
1094/1152 (95.0) 
7/1152 (0.6) 
1/1152 (0.1) 
50/1152  (4.3) 
 
3404/3718 (91.5) 
48/3718  (1.3) 
18/3718 (0.5) 
248/3718 (6.7) 
 
16 
 
0.001 
Collection year 
2003 
2004 
2005 
 
330/1154 (28.6) 
406/1154 (35.2) 
418/1154 (36.2) 
 
1028/3736 (27.5) 
1359/3736 (36.4) 
1349/3736 (36.1) 
 
0.72 
 
0.69 
Province 
Gauteng 
Eastern Cape 
Western Cape 
Mpumalanga 
KwaZulu Natal 
North West 
Free State 
Limpopo 
 
539/1154 (46.7) 
95/1154 (8.2) 
123/1154 (10.7) 
96/1154 (8.3) 
141/1154 (12.2) 
5/1154  (0.4) 
107/1154  (9.3) 
48/1154  (4.2) 
 
2167/3736 (58.0) 
67/3736 (1.8) 
664 /3736 (17.8) 
62/3736  (1.7) 
481/3736  (12.9) 
1/3736 (0.0) 
257/3736  (6.9) 
37/3736  (0.9) 
 
349 
 
<0.001 
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3.8.2 Clinical, microbiologic and other characteristics (Tables 3.4 and 3.5) 
There were significant differences observed in most clinical factors between 
meningitis and other invasive disease. The following factors had higher proportions 
of cases with other invasive disease compared to meningitis: cotrimoxazole 
prophylaxis (26% versus 18%), HIV-positive cases (88% versus 82%), cases with 
underlying medical illness (67% versus 44%), cases who received prior antibiotics 
within 2 months before first positive pneumococcal isolate (19% versus 14%), cases 
with cotrimoxazole resistant isolates (60% versus 54%) and smokers (4% versus 
2%).  
 
Those with meningitis were more likely to have a Pitt bacteraemia score ≥4 (13% 
versus 7%) and a higher proportion of them took antibiotics 24 hours before first 
positive blood/CSF culture (10% versus 5%). There was no difference in proportion 
of nosocomial infection in the two groups.  
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Table 3.4: Comparison of microbiologic and other characteristics of cases of 
meningitis versus other invasive pneumococcal disease amongst patients’ from 
enhanced sites with case report forms. 
 
 
 
 
Meningitis 
 
Other invasive disease 
 
 
Characteristic 
 
N (%) N (%) X
2
 P 
 
Vaccine-serotypes
 
No 
Yes 
 
652/1089 (59.9) 
437/1089 (40.1) 
 
1954 (60.4) 
1279 (39.6) 
 
0.10 
 
0.74 
Nosocomial Infection 
No 
Yes 
 
1131/1156(98.0) 
23/1156 (2.0) 
 
3624/3736 (97.0) 
112/3736 (3.0) 
 
3.3 
 
0.06 
Smoking 
No 
Yes 
 
1129/1154 (97.8) 
25/1154 (2.2) 
 
3575/3736 (95.7) 
161/3736 (4.3) 
 
11 
 
0.001 
Alcohol abuse 
No 
Yes 
 
1122/1154 (97.2) 
32/1154 (2.8) 
 
3633/3736 (97.2) 
103/3736 (2.8) 
 
0.0008 
 
0.98 
Penicillin NonS# 
No 
Yes 
 
789/1090 (72.4) 
301/1090 (27.6) 
 
2302/3233 (71.2) 
931/3233 (28.8) 
 
0.56 
 
 
0.46 
 
Ceftriaxone NonS
 
No 
Yes 
 
1084/1090  (99.5) 
6/1090  (0.6) 
 
32025/3233  (0.8) 
8/3233  (99.2) 
 
0.57 
 
 
0.45 
 
Cotrimoxazole NonS
 
No 
Yes 
 
505/1090  (46.3) 
585/1090  (53.7) 
 
1296/3233  (40.0) 
1937/3233  (60.0) 
 
13 
 
 
<0.001 
 
Erythromycin NonS
 
No 
Yes 
 
954/1090  (87.5) 
136/1090  (12.5) 
 
2798/3233  (86.6) 
435/3233  (13.5) 
 
0.68 
 
 
0.41 
 
Chloramphenicol NonS
 
No 
Yes  
 
1058/1090  (97.1) 
32/1090  (2.9) 
 
3152 (97.5) 
81 (2.5) 
 
0.59 
 
0.44 
 
# NonS: Streptococcus pneumoniae isolates not susceptible to the mentioned 
antibiotics. 
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Table 3.5: Comparison of clinical characteristics of cases of meningitis versus 
other invasive pneumococcal disease amongst patients’ from enhanced sites 
with case report forms 
 
 
 
 
Meningitis 
 
Other invasive disease 
 
 
Characteristic 
 
N (%) N (%) X
2
 P 
 
Cotrimoxazole prophylaxis 
No 
Yes 
 
651/796 (81.8) 
145/796 (18.2) 
 
1922/2618 (73.4) 
696/2618 (26.6) 
 
23 
 
<0.001 
HIV infection 
No 
Yes 
 
112/624 (18.0) 
512/624 (82.0) 
 
284/2346 (12.1) 
2062/2346 (87.9) 
 
14.6 
 
<0.001 
Pitt bacteraemia score 
  <4 
  ≥4 
 
708/814 (87.0) 
106/814 (13.0) 
 
2467/2657 (92.8) 
190/2657 (7.2) 
 
27.7 
 
<0.001 
Underlying illness 
No 
Yes 
 
323/578 (55.9) 
255/578 (44.1) 
 
777/2349 (33.1) 
1572/2349 (66.9) 
 
102.8 
 
 
<0.001 
 
Antibiotic treatment past 24 
hours 
No 
Yes 
 
 
884/977 (90.5) 
93//977 (9.5) 
 
 
2991/3135 (95.4) 
144/3135 (4.6) 
 
 
33 
 
 
<0.001 
Antibiotic treatment past 2 
months 
No 
Yes 
 
 
667/775 (86.1) 
108/775 (13.9) 
 
 
 
2004/2471 (81.1) 
467/2471 (18.9) 
 
 
 
9.97 
 
 
0.002 
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3.9 Comparison of characteristics of patients who received and those who did 
not receive antibiotics within 2 months prior to positive blood/CSF culture 
(Table 3. 6) 
There were significant differences observed in age distribution between the two 
groups (P=<0.001). Of those who received antibiotics 65% were children < 5 years 
and 35% were those aged between 5 and 65 years. Among patients aged 25-44 
years, 13% received antibiotics compared to 36% in the same age group who did 
not receive antibiotics.  
 
There was also a significant difference in provincial distribution with a higher 
proportion of patients who received antibiotics reported from Western Cape and 
Gauteng Provinces (39.8% and 38.4%) respectively. These observed differences 
were statistically significant (P=<0.001). Other significant differences were 
observed in distribution of vaccine-serotypes (61.4% versus 35.7%, P=<0.001), 
cotrimoxazole prophylaxis (64.9% versus 14.4%, P=<0.001), HIV infection (93.4% 
versus 83.2%, P<0.001) and underlying illness (81.9% versus 61.5% P=<0.001). 
Patients who received antibiotics had higher proportions of antibiotic resistant 
isolates e.g. penicillin (46.2% versus 25.9%, P=<0.001). No differences however 
were observed in severity of illness (P=0.49).  
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Table 3.6: Comparison of characteristics of patients who received and those 
who did not receive antibiotics 2 months prior to positive blood/CSF culture 
 
 Received 
antibiotics 
Did not receive 
antibiotics 
 
 
Characteristic N (%) N (%) X
2
 P value 
Age group in years 
<1 
1-4 
5-14 
15-24 
25-44 
45-64 
≥65 
 
180/575 (31.3) 
197/575 (34.3) 
81/575 (14.1) 
13/575 (2.3) 
75/575 (13.0) 
23/575 (4.0) 
6/575 (1.0) 
 
524/2668 (19.6) 
408/2668 (15.3) 
255/2668 (9.6) 
173/2668 (6.5) 
979/2668 (36.7) 
261/2668 (9.7) 
68/2668 (2.6) 
 
249 
 
 
<0.001 
Sex 
Male 
Female 
 
289/575 (50.3) 
286/575 (49.7) 
 
1338/2667 (50.2) 
1329/2667 (49.8) 
 
0.002 
 
0.97 
 
Province 
Gauteng 
Eastern Cape 
Western Cape 
Mpumalanga 
KwaZulu Natal 
North West 
Free State 
Limpopo 
 
 
221/575 (38.4) 
28/575 (4.9) 
229/575 (39.8) 
10/575 (1.7) 
29/575 (5.0) 
1/575 (0.2) 
45/575 (7.9) 
12 /575(2.1 
 
 
1488/2671 (55.7) 
117/2671 (4.4) 
280/2671 (10.5) 
123/2671 (4.6) 
292/2671 10.9) 
3/2671  (0.1) 
314/2671 (11.8) 
54/2671 (2.0) 
 
 
 
319 
 
 
<0.001 
 
Serotypes 
Non-vaccine 
Vaccine 
 
201/520 (38.6) 
319/520 (61.4) 
 
1529/2379 (64.3) 
850/2379 (35.7) 
 
116 
 
 
<0.001 
 
Cotrimoxazole prophylaxis 
No 
Yes 
 
183/522 (35.1) 
339/522 (64.9) 
 
2168/2532 (85.6) 
364/2532 (14.4) 
 
624 
 
<0.001 
HIV infection 
No 
Yes 
 
28/424 (6.6) 
396 /424 (93.4) 
 
289/1722 (16.8) 
1433/1722 (83.2) 
 
28 
 
<0.001 
 
Underlying illness 
No 
Yes 
 
 
66/365 (18.1) 
299/365 (81.9) 
 
 
608/1577 (38.5) 
969/1577 (61.5) 
 
 
54.8 
 
 
<0.001 
Pitt bacteraemia score 
<4 
≥4 
 
325/353 (92.0) 
28/353 (7.9) 
 
1710/1837 (93.1) 
127/1837 (6.9) 
 
0.47 
 
0.49 
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Cd4 count 
Low 
Normal 
 
 
104/159 (65.4) 
55/159 (34.6) 
 
 
155 /546 (28.4) 
391/546 (71.6) 
 
 
2.2 
 
 
0.13 
 
Penicillin NonS# 
No 
Yes 
 
 
280/520 (53.9) 
240/520 (46.2) 
 
 
1763/2380 (74.1) 
617/2380 (25.9) 
 
 
83.9 
 
 
 
<0.000 
 
Ceftriaxone NS 
No 
Yes 
 
 
507/520 (97.5) 
13/520 (2.5) 
 
 
2373/2380 (99.7) 
7/2380 (0.3) 
 
 
30 
 
 
<0.001 
 
Cotrimoxazole NS 
No 
Yes 
 
 
94/520 (18.1) 
426 /520 (81.9) 
 
 
1102/2380 (46.3) 
1278/2380 (53.7) 
 
 
140 
 
 
<0.001 
 
Erythromycin NS 
No 
Yes 
 
 
380/520 (73.1) 
140/520 (26.9) 
 
 
2127/2380 (89.4) 
253/2380 (10.6) 
 
 
96.7 
 
 
<0.001 
 
Chloramphenicol NS 
No 
Yes 
 
 
508/520 (97.6) 
12/520 (2.3) 
 
 
2321/2380 (97.5) 
59/2380 (2.5) 
 
 
0.05 
 
 
0.82 
 
 
# NonS: Streptococcus pneumoniae isolates not susceptible to the mentioned 
antibiotics. 
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3.10 Comparison of characteristics of HIV-positive and HIV-negative patients 
with invasive pneumococcal disease (Table 3.7) 
Data for HIV was available for 2970 (61%) of our study sample; of this 2577 (87%) 
were HIV co-infected. Age distribution between the two groups was significantly 
different (P=<0.001). Of those who had HIV co-infection, 34% were children <5 
years and 41% were adults aged 25-44 years while those who did not have HIV co-
infection 56% were children <5 years and 15% were adults aged 25-44 years. 
 
There was higher proportion of HIV-infected patients reported from Gauteng 
(64.6%) and Western Cape (11.7%) provinces compared to (55%) from Gauteng 
and (19.6%) from Western Cape in the HIV-negative patients. This observed 
difference was statistically significant (P=<0.001). Other significant differences 
were observed in distribution of vaccine-serotypes (42.4% versus 34.3%, P <0.001), 
cotrimoxazole prophylaxis (38.7% versus 8.0%, P=<0.001) and underlying illness 
(65.4% versus 55.1%, P=<0.001). There was a higher proportion of female patients 
with HIV infection (52% versus 41%) and also a higher proportion of antibiotic 
resistant isolates among the HIV co-infected patients e.g. penicillin (32.0% versus 
25.0%, P=<0.001). There were no differences observed in severity of illness 
between HIV-positive and HIV-negative patients (P=0.14).  
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Table 3.7: Comparison of characteristics of HIV-positive and HIV-negative 
patients with invasive pneumococcal disease  
 
 
 
 
 
HIV-positive  
 
 
HIV-negative  
 
 
 
Characteristic 
 
N (%) N (%) X
2
 P value 
 
Age group in years 
<1 
1-4 
5-14 
15-24 
25-44 
45-64 
≥65 
 
393/2574 (15.3) 
488/2574 (19.0) 
235 /2574 (9.1) 
145/2574  (5.6) 
1061/2574  (41.2) 
235/2574  (9.1) 
17/2574  (0.7) 
 
131/393 (33.3) 
92 /393 (23.4) 
45/393  (11.5) 
20/393  (5.1) 
60 /393 (15.3) 
33/393  (8.4) 
12/393  (3.0) 
 
 
 
149 
 
 
 
 
<0.001 
Sex 
Male 
Female 
 
1235/2574  (48.0) 
1339/2574  (52.0) 
 
230/392 (59.0) 
162/392 (41.0) 
 
15 
 
<0.001 
 
Province 
Gauteng 
Eastern Cape 
Western Cape 
Mpumalanga 
KwaZulu Natal 
North West 
Free State 
Limpopo 
 
 
1664/2577 (64.6) 
95 /2577 (3.7) 
301/2577  (11.7) 
56/2577  (2.2) 
230/2577  (8.9) 
4/2577  (0.2) 
205/2577  (7.9) 
22/2577  (0.8) 
 
 
216/393   (55.0) 
29/393   (7.4) 
77/393   (19.6) 
4/393   (1.0) 
19/393   (4.8) 
0/393    (0.0) 
43/393   (10.9) 
5/393   (1.3) 
 
 
 
 
47 
 
 
 
 
<0.001 
 
 
Serotypes 
Vaccine 
Non-vaccine 
 
 
956/2253 (42.4) 
1297/2253  (57.6) 
 
 
121/353 (34.3) 
232/353 (65.7) 
 
 
8.4 
 
 
0.004 
Cotrimoxazole 
prophylaxis 
Yes 
No 
 
 
737/1906 (38.7) 
1169/1906 (61.3) 
 
 
26/322 (8.0) 
296/322 (92.0) 
 
 
114 
 
 
<0.001 
 
Underlying illness 
Yes 
No 
 
 
1107/1693 (65.4) 
586/1693 (34.6) 
 
 
129/234 (55.1) 
105/234 (44.9) 
 
 
9.4 
 
 
 
0.002 
 
 
Pitt bacteraemia score 
<4 
≥4 
 
 
1683/1823 (92.3) 
140 /1823 (7.7) 
 
 
 
256 /285 (89.8) 
29/285 (10.2) 
 
 
2.0 
 
 
0.149 
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Penicillin NonS# 
No 
Yes 
 
1532/2254 (68.0) 
722/2254 (32.0) 
 
265/353 (75.0) 
88/353 (25.0) 
 
7.0 
 
 
0.007 
 
Ceftriaxone NonS 
No 
Yes 
 
 
2237/2254 (99.2) 
17/2254 (0.8) 
 
 
350/353 (99.1) 
3/353 (0.9) 
 
 
0.03 
 
 
0.85 
 
Cotrimoxazole NonS 
No 
Yes 
 
 
812/2254  (36.0) 
1442/2254  (64.0) 
 
 
166/353  (47.0) 
187/353  (53.0) 
 
 
15.8 
 
 
<0.001 
 
Erythromycin NonS 
No 
Yes 
 
 
1907/2254  (84.6) 
347/2254  (15.4) 
 
 
319/353  (90.4) 
34/353  (9.6) 
 
 
8.1 
 
 
0.004 
 
Chloramphenicol NonS 
No 
Yes 
 
 
2183/2254  (96.9) 
71/2254  (3.1) 
 
 
345/353  (97.7) 
8/353  (2.3) 
 
 
0.81 
 
 
0.37 
 
 
# NonS: Streptococcus pneumoniae isolates not susceptible to the mentioned 
antibiotics 
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3.11 Outcome 
The overall case fatality rate was 1360/4890 (27.8%) of which 911 (67%) patients 
died within 2 days of admission and 449 (33%) died between 2 days and 30 days of 
admission. The median age of those who died was 30 years (range 0 to 86 years). 
The median duration of outcome from a positive blood/CSF culture was 6 hospital 
days. Meningitis had a higher case fatality rate 520/1154 (45.1%) compared to other 
invasive disease 840/3736 (22.5%). 
 
3.12 Risk factors associated with mortality in all eligible patients with IPD 
3.12.1 Univariate analysis (Tables 3.8.1 –3.8.4). 
The following factors were found to be significantly associated with mortality on 
univariate analysis using Pearsons X
2
 test at P≤0.1. 
 Demographic factors: age, sex, race and province. 
 Microbiologic factors: specimen type and cotrimoxazole resistance. 
 Clinical factors: Pitt bacteraemia score, prior antibiotic use 24 hours before 
first positive blood/CSF culture, prior antibiotic use within 2 months before 
first positive blood/CSF culture and HIV status.  
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Table 3.8.1: Univariate analysis of demographic factors that could potentially 
influence mortality in patients with invasive pneumococcal disease. 
 
 
Risk Factor 
 
Case Fatality Rate (%) 
 
X
2
 
 
P value 
Age group in years 
<1 
1-4 
5-14 
15-24 
25-44 
45-64 
=>65 
 
277/921 (30.1) 
151/849 (17.8) 
77/467 (16.5) 
72/307 (23.4) 
498/1693 (29.4) 
225/514 (43.8) 
56/131 (42.8) 
 
159.68 
 
 
<0.001 
Sex 
Male 
Female 
 
665/2481 (26.8) 
695/2404 (28.9) 
 
2.7 
 
 
0.10 
Race 
Black 
White 
Asian 
Coloured 
 
1270/4498 (28.2) 
15/55  (27.3) 
6/19 (31.6) 
62/298 (20.8) 
 
 
7.8 
 
 
0.05 
Collection year 
2003 
2004 
2005 
 
385/1358 (28.4) 
503/1765 (28.5) 
472/1767 (26.7) 
 
1.68 
 
0.43 
Province 
Gauteng 
Eastern Cape 
Western Cape 
Mpumalanga 
KwaZulu Natal 
North West 
Free State 
Limpopo 
 
787/2706 (29.1) 
67/162 (41.4) 
136/787 (17.3) 
64/158 (40.5) 
170/622 (27.3) 
5/6 (83.3) 
99/364 (27.2) 
32/85 (37.7) 
 
 
86.58 
 
<0.001 
 
 
Case Fatality Rate: Number of deaths /Number of patients (%).Number of deaths 
included only those who died within 30 days of admission 
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Table 3.8.2: Univariate analysis of microbiologic and other factors that could 
potentially influence mortality in patients with invasive pneumococcal disease 
 
 
Risk Factor 
 
Case Fatality Rate
f
(%) 
 
X
2
 
 
P value 
Vaccine-serotypes 
No  
Yes  
 
735/2606 (28.2) 
472/1716 (27.5) 
 
0.25 
 
 
0.617 
Specimen site 
Other† 
CSF 
 
840/3737 (22.5) 
520 /1154 (45.0) 
 
224 
 
<0.001 
Nosocomial infection 
No 
Yes 
 
1323/4755 (27.8) 
37/135 (27.4) 
 
0.01 
 
0.92 
Alcohol use 
No 
Yes 
 
1321/4755 (27.8) 
39/135 (28.9) 
 
0.08 
 
0.77 
Current smoker 
No 
Yes 
 
1318/4704  (28.0) 
42/186 (22.6) 
 
2.64 
 
0.10 
 
†Other specimens include blood, joint fluid, peritoneal fluid and pleural fluid. 
f 
Case Fatality Rate: Number of deaths /Number of patients (%). Number of deaths 
included only those who died within 30 days of admission 
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Table 3.8.3: Univariate analysis of the potential influence of antibiotic 
resistance on mortality in patients with invasive pneumococcal disease 
 
 
Risk Factor 
 
Case Fatality Rate (%)  
 
X
2
 
 
P 
Penicillin NonS# 
 
No 
Yes 
 
868/3091 (28.1) 
340/1232 (27.6) 
 
0.10 
 
 
0.75 
Ceftriaxone NonS 
No 
Yes 
 
1201/4292 (28.0) 
7/31 (22.6) 
 
0.44 
 
0.50 
 
Rifampicin NonS 
No 
Yes 
 
1158/4115 (28.0) 
50/208 (24.0) 
 
1.66 
 
0.198 
Cotrimoxazole NonS 
No 
Yes 
 
532/1801 (29.5) 
676/2522 (26.8) 
 
3.9 
 
 
0.05 
 
Erythromycin NonS 
No 
Yes 
 
1040/3752 (27.7) 
168/571 (29.4) 
 
0.71 
 
0.398 
Clindamycin NonS 
No 
Yes 
 
1082/3907 (27.7) 
126/416 (30.3) 
 
1.26 
 
 
0.26 
Chloramphenicol NonS 
No 
Yes 
 
32/113 (28.3) 
1176/4210 (27.9) 
 
0.008 
 
 
0.93 
 
Tetracycline NonS 
No 
Yes 
 
989/3569 (27.7) 
219/745 (29.0) 
 
0.55 
 
 
0.46 
 
 
# NonS: Streptococcus pneumoniae isolates not susceptible to the mentioned 
antibiotics. 
f 
Case Fatality Rate: Number. of deaths /Number. of patients (%).Number of deaths 
included only those who died within 30 days of admission 
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Table 3.8.4: Univariate analysis of clinical factors that could potentially 
influence mortality in patients with invasive pneumococcal disease 
 
 
 
Risk Factor 
 
Case Fatality Rate (%) 
 
X
2
 
 
P 
Pitt bacteraemia score 
 <4 
 ≥4 
 
765/3175 (24.1) 
195/296 (65.9) 
 
236.3 
 
<0.001 
 
HIV infection 
No 
Yes 
 
69/396 (17.4) 
655/2574 (25.5) 
 
11.98 
 
 
0.001 
Cotrimoxazole prophylaxis 
No 
Yes 
 
534/2573 (20.8) 
170/841 (20.2) 
 
0.11 
 
0.74 
Prior antibiotic use 
(24 hours) 
No  
Yes 
 
 
979/3875 (25.3) 
72/237 (30.4) 
 
 
3.07 
 
 
 
0.08 
 
Prior antibiotic use 
(2 months) 
No 
Yes 
 
 
547/2671 (20.5) 
138/575 (24.0) 
 
3.5 
 
0.06 
 
f 
Case Fatality Rate: No. of deaths /No. of patients (%). Number of deaths included 
only those who died within 30 days of admission. 
 
3.12.2 Multivariate analysis (Table 3.9) 
There were no interactions observed. The following factors were significantly 
associated with mortality in multivariate analysis adjusting for the effects of each in 
the model.  
 
3.12.2.1 Demographic factors:  
• Age: Compared to patients less than 1 year of age those aged 1-4 years (OR 
0.47, CI 0.29 – 0.75, P=0.002), 5-14 years (OR 0.37, CI 0.20 – 0.66, 
P=0.001) 15-24 years (OR 0.28, CI 0.12 – 0.64, P=0.003) and 25-44 years 
(OR 0.56, CI 0.37 – 0.83, P=0.005) were less likely to die. Patients aged 15-
24 years had lowest likelihood of dying while patients aged 45-64 (OR 1.13, 
CI 0.66 – 1.94, P=0.65) and ≥65 (OR 1.0, CI 0.24 – 4.21 P=0.99) were not 
at significantly different risk of dying as compared to those <1 year old. 
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• Province: Compared to patients from Gauteng, patients from Mpumalanga 
(OR 2.0 CI 0.96 – 4.1, P= 0.058), Eastern Cape (OR 1.6, CI 0.91 – 2.8, 
P=0.101) and KwaZulu Natal (OR 1.4, CI 0.80 – 2.4, P=0.24) were more 
likely to die. However, this was not a statistically significant association. 
Patients from Western Cape were significantly less likely to die (OR 0.27, 
CI 0.15 – 0.50, P=<0.001) compared to other provinces. 
 
3.12.2.2 Microbiologic factors: 
• Meningitis: Patients with meningitis were 2.8 times more likely to die 
compared to those with other invasive pneumococcal disease i.e. 
bacteraemia (OR 2.8, CI 1.9 – 3.9, P=<0.001)  
 
3.12.2.3 Clinical factors: 
• HIV Infection: HIV-positive invasive pneumococcal disease patients had 
almost 3 times the risk of dying compared to HIV-negative invasive 
pneumococcal disease patients (OR 2.8, CI 1.6 – 4.6, P=<0.001). 
• Pitt bacteraemia score: Patients admitted with severe state of illness (Pitt 
bacteraemia score ≥4) were nearly 5 times at risk of dying (OR 4.7, CI 2.8 – 
7.7, P=<0.001).  
• Prior antibiotic use within 2 months before first positive culture: Patients 
who took an antibiotic other than cotrimoxazole prophylaxis within two 
months prior to admission with an episode of invasive disease had two times 
the risk of dying from the episode compared to patients who did not take an 
antibiotic (OR 2.1, CI 1.4 – 3.1, P=<0.001).  
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Table 3.9: Multivariate analysis of factors potentially associated with mortality 
in all invasive pneumococcal disease  
 
 
Risk Factor 
Odds Ratio 
(Adjusted) 
 
95% CI 
 
P 
Age group in years 
<1 
1-4 
5-14 
15-24 
25-44 
45-64 
=>65 
 
1.0 
0.47 
0.37 
0.28 
0.56 
1.13 
1.0 
 
Reference 
0.29 – 0.75 
0.20 – 0.66 
0.12 – 0.64 
0.37 – 0.83 
0.66 – 1.94 
0.24 – 4.21 
 
- 
0.002 
0.001 
0.003 
0.005 
0.65 
0.99 
Province 
Gauteng 
Eastern Cape 
Western Cape 
Mpumalanga 
KwaZulu Natal 
North West 
Free State 
Limpopo 
 
1.0 
1.6 
0.27 
2.0 
1.4 
N/A 
0.91 
0.36 
 
Reference 
0.91 – 2.8 
0.15 – 0.50 
0.96 – 4.1 
0.80 – 2.4 
- 
0.60 – 1.4 
0.08 – 1.7 
 
- 
0.101 
<0.001 
0.058 
0.24 
- 
0.68 
0.20 
Clinical syndrome 
Other IPD 
Meningitis  
 
1.0 
2.8 
 
Reference 
1.9 – 3.9 
 
- 
<0.001 
HIV infection 
No 
Yes  
 
1.0 
2.8 
 
Reference 
1.6 – 4.6 
 
- 
<0.001 
Pitt bacteraemia score 
<4 
≥4  
 
1.0 
4.7 
 
Reference 
2.8 – 7.7 
 
- 
<0.001 
Prior antibiotic use 
(2months) 
N o 
Yes 
 
 
1.0 
2.1 
 
 
Reference 
1.4 – 3.1 
 
 
- 
<0.001 
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We considered that risk factors for death might differ between patients with 
meningitis as compared to other IPD as meningitis is associated with a higher 
mortality overall. Pharmacodynamic factors and management may also be very 
different between these groups.  
 
3.13 Risk factors for death in patients with meningitis (Table 3.10). 
3.13.1 Univariate analysis 
The following factors were significant risk factors for death on univariate analysis 
in the meningitis group and were included in the multivariable logistic regression 
model.  
 Demographic factors: age, race and province. 
 Microbiologic factors: vaccine- serotypes and penicillin resistance. 
 Clinical factors: HIV status, Pitt bacteraemia, prior antibiotic use within 2 
months before first positive blood /CSF culture  
 
3.13.2 Multivariate analysis  
Factors significantly associated with mortality in multivariate analysis.  
3.13.2.1 Demographic factors:  
• Age: Children less than 1 year of age and adults ≥45 years with 
pneumococcal meningitis were more likely to die compared to other age 
groups.  
• Province: Patients living in Eastern Cape had 2.3 times the risk of dying 
(OR 2.3, CI 1.4 – 3.9, P=0.002) while those from Mpumalanga had 3.1 
times the risk of dying (OR 3.1, CI 1.6 – 6.2, P=0.001) if they had an 
episode of pneumococcal meningitis. Patients from Western Cape had 0.26 
times the risk of dying (OR 0.26, CI 0.15 – 0.48, P=<0.001).  
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3.13.2.2 Clinical factors: 
• HIV Infection: HIV-positive pneumococcal meningitis patients had nearly 
twice the risk of dying compared to HIV-negative meningitis patients (OR 
2.2, CI 1.3 – 3.6, P=0.002). 
• Pitt bacteraemia score: Pneumococcal meningitis patients admitted to 
hospital with Pitt bacteraemia score ≥4 had 5 times the risk of dying (OR 
5.0, CI 3.1 – 8.1, P=<0.001).  
• Prior antibiotic use within 2 months before first positive blood/CSF culture: 
The risk of dying in pneumococcal meningitis patients with a history of 
prior antibiotics use 2 months before admission was twice those in patients 
without prior antibiotic use (OR 2.0, CI 1.4 – 3.0, P=<0.001).
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Table 3.10: Univariate and multivariate analysis of risk factors 
influencing mortality in patients with pneumococcal meningitis 
 
 
 
 
Univariate analysis 
 
Multivariate analysis 
 
Risk Factor 
 
Case Fatality 
Rate (%) 
 
OR (95% CI) 
Unadjusted 
 
P 
 
OR (95% CI) 
Adjusted 
 
P 
Age group  
<1 
1-4 
5-14 
15-24 
25-44 
45-64 
≥65 
 
117/296(39.5) 
43/138 (31.2) 
45/144 (31.2) 
35/94 (37.2) 
205/370(55.4) 
70/101(69.3) 
4 /9 (44.4) 
 
1.0 
0.69 (0.5, 1.1) 
0.69 (0.5, 1.1) 
0.90 (0.6, 1.5) 
1.9 (1.4, 2.6) 
3.5 (2.1, 5.6) 
1.2 (0.3, 4.7) 
 
Reference 
0.09 
0.09 
0.69 
<0.001 
<0.001 
0.77 
 
1.0 
0.42 (0.27,0.67) 
0.42 (0.23,0.74) 
0.27 (0.12,0.61) 
0.52 (0.35,0.77) 
1.1 (0.63, 1.8) 
0.71 (0.17,2.9) 
 
Reference 
<0.001 
0.003 
0.002 
0.001 
0.80 
0.64 
Sex 
Male 
Female 
 
258/589(43.8) 
262/564(46.6) 
 
1.0 
1.1 (0.9, 1.4) 
 
Reference 
0.37 
 
 
NI* 
 
 
- 
Race 
Black 
White 
Asian 
Coloured 
 
508/1094(46.4) 
2/7  (28.6) 
1/1 (100) 
9/50(18.0) 
 
1.0 
0.46 (0.1, 2.4) 
NA 
0.25 (0.1, 0.5) 
 
Reference 
0.36 
- 
<0.001 
 
 
NS** 
 
 
- 
Collection year 
2003 
2004 
2005 
 
146/330(44.2) 
193/406 (47.5) 
181/418 (43.3) 
 
1.0 
1.1 (0.9, 1.5) 
0.96 (0.7,1.3) 
 
Reference 
0.37 
0.79 
 
 
NI 
 
 
- 
Serotypes 
Non-vaccine 
Vaccine 
 
323/652 (49.5) 
171/437 (39.1) 
 
1.0 
0.65 (0.5, 0.8) 
 
Reference 
0.001 
 
 
NS 
 
 
- 
Province 
Gauteng 
Eastern Cape 
Western Cape 
Mpumalanga 
KwaZulu Natal 
North West 
Free State 
Limpopo 
 
263/539 (48.8) 
49/95 (51.6) 
26/123 (21.1) 
45/96 (46.9) 
64/141 (45.4) 
5/5 (100.0) 
44/107 (41.0) 
24/48 (50.0) 
 
1.0 
1.1 (0.7, 1.7) 
0.28 (0.2, 0.4) 
0.93 (0.6, 1.4) 
0.87 (0.6, 1.2) 
N/A 
0.73 (0.5, 1.1) 
1.0 (0.6, 1.9) 
 
Reference 
0.62 
<0.001 
0.73 
0.47 
 
0.15 
0.87 
 
1.0 
2.3 (1.4, 3.9) 
0.26 (0.15,0.48) 
3.1 (1.6, 6.2) 
1.5 (0.88,2.5) 
N/A 
1.0 (0.66, 1.5) 
0.44 (0.09,2.0) 
 
- 
0.002 
<0.001 
0.001 
0.14 
 
0.97 
0.29 
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Nosocomial infection 
No 
Yes 
 
510 (45.1) 
10 (43.5) 
 
1.0 
0.93 (0.4,2.2) 
 
Reference 
0.88 
 
 
NI* 
 
 
- 
Current smoker 
No 
Yes  
 
510 (45.2) 
10 (40.0) 
 
1.0 
0.8 1(0.4, 1.8) 
 
Reference 
0.60 
 
 
NI 
 
 
- 
HIV infection 
No 
Yes  
 
21/112 (18.8) 
241/512(47.0) 
 
1.0 
3.9 (2.3, 6.4) 
 
Reference 
<0.001 
 
 
2.2 (1.3,3.6) 
 
 
0.002 
Alcohol use 
No 
Yes  
 
503/1122(44.8) 
17/32 (53.1) 
 
1.0 
1.4 (0.7, 2.8) 
 
Reference 
0.35 
 
 
NI 
 
 
- 
Underlying illnesses  
No 
Yes 
 
137/323 (42.4) 
120/255 (47.1) 
 
1.0 
1.2 (0.9, 1.7) 
 
Reference 
0.27 
 
 
NI 
 
 
- 
Pitt bacteraemia score 
<4 
≥4  
 
288/708 (40.7) 
81/106 (76.4) 
 
1.0 
4.7 (2.9, 7.6) 
 
Reference 
<0.001 
 
 
5.0 (3.1,8.1) 
 
 
<0.001 
Prior antibiotic use (24 
hours) 
No 
Yes  
 
 
377/884 (42.7) 
36/93 (38.7) 
 
 
1.0 
0.84 (0.5, 1.3) 
 
 
Reference 
0.47 
 
 
 
NI 
 
 
 
- 
Prior antibiotic use (2 
months) 
No 
Yes  
 
 
244/667 (36.6) 
41/108 (38.0) 
 
 
1.0 
1.1 (0.7, 1.6) 
 
 
Reference 
0.78 
 
 
 
2.0 (1.4,3.0) 
 
 
 
<0.001 
Cotrimoxazole 
prophylaxis  
No 
Yes  
 
 
228/651 (35.0) 
59/145 (40.7) 
 
 
1.0 
1.3 (0.9, 1.8) 
 
 
Reference 
0.20 
 
 
NI 
 
 
- 
Penicillin NonS# 
No 
Yes 
 
374/789 (47.4) 
121/301 (40.2) 
 
1.0 
0.75 (0.6, 0.9) 
 
Reference 
0.03 
 
NS 
 
 
- 
Ceftriaxone NonS 
No 
Yes 
 
493/1084(45.5) 
2/6 (33.3) 
 
1.0 
0.60 (0.1, 3.3) 
 
Reference 
0.56 
 
NI 
 
 
- 
Chloramphenicol Non 
No 
Yes 
 
479/1058(45.3) 
16 /32(50.0) 
 
1.0 
1.2 (0.6, 2.4) 
 
Reference 
0.60 
 
NI 
 
- 
*NI: Factors not significant on univariate analysis (P>0.10) were omitted in logistic 
regression model. 
**NS: Factors not significant on multivariate logistic regression analysis  
f 
Number of deaths included only those who died within 30 days of admission. 
# NonS: Streptococcus pneumoniae isolates not susceptible to the mentioned 
antibiotics. 
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3.14 Risk factors for death in patients with other invasive pneumococcal 
disease (Table 3.11) 
3.14.1 Univariate analysis  
The following risk factors significant on univariate analysis stratified for other 
invasive disease were included in the multivariable logistic regression model: 
 Demographic factors: age, and province. 
 Microbiologic factors: vaccine-serotypes and erythromycin resistance. 
 Clinical factors: HIV status, Pitt bacteraemia score, prior antibiotic use 
within 2 months before first positive blood/CSF culture.  
 
3.14.2 Multivariate analysis  
Risk factors significantly associated with mortality in patients with other invasive 
pneumococcal disease in multivariate analysis were:  
 
3.14.2.1 Demographic factors:  
• Age: Children less than 1 year of age and adults ≥45 years of age with other 
invasive pneumococcal disease were more likely to die compared to other 
age groups.  
• Province: Patients who lived in Eastern Cape had 2.7 times the risk of dying 
(OR 2.7, CI 1.7 – 4.2, P=<0.001) while those from Mpumalanga had. 3.3 
times the risk of dying (OR 3.3, CI 2.1 – 5.2, P=<0.001) if they had other 
invasive pneumococcal disease. Patients from Western Cape showed a less 
likelihood of dying (OR 0.48, CI 0.33 – 0.70, P=<0.001). 
 
3.14.2.2 Clinical factors: 
• Pitt bacteraemia score: Patients with Pitt bacteraemia of ≥4 with a positive 
blood culture for pneumococci had 5.5 times the risk of dying (OR 5.5, CI 
3.8 – 7.9, P=<0.001). 
• Patients with history of prior antibiotic use within 2 months before first 
positive blood/CSF culture had 1.8 times the risk of dying (OR 1.8, CI 1.3 – 
2.4, P=<0.001). 
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Table 3.11 Univariate and multivariate analysis of risk factors influencing 
mortality in patients with other invasive disease 
 
 
 
 
Univariate analysis 
 
Multivariate analysis 
 
Risk Factor 
 
Case Fatality 
Rate (%) 
 
OR (95% CI) 
Unadjusted 
 
P 
 
OR (95% CI) 
Adjusted 
 
P 
Age group  
<1 
1-4 
5-14 
15-24 
25-44 
45-64 
≥65 
 
160/625 (25.6) 
108/711 (15.2) 
32/323 (9.9) 
37/213 (17.4) 
293/1323(22.2) 
155/413 (37.5) 
52/122 (42.6) 
 
1.0 
0.52 (0.39,0.68) 
0.32 (0.21,0.48) 
0.61 (0.41,0.90) 
0.83 (0.66, 1.0) 
1.7 (1.3, 2.3) 
2.2 (1.4, 3.2) 
 
Reference 
<0.001 
<0.001 
0.015 
0.09 
<0.001 
<0.001 
 
1.0 
0.41 (0.28,0.60) 
0.39 (0.25,0.61) 
0.24 (0.12,0.48) 
0.57 (0.42,0.77) 
1.3 (0.88, 1.9) 
1.5 (0.76,2.8) 
 
Reference 
<0.001 
<0.001 
<0.001 
<0.001 
0.18 
0.25 
Sex 
Male 
Female 
 
407/1892(21.5) 
433/1840(23.5) 
 
1.0 
1.1 (0.96,1.3) 
 
Reference 
0.14 
 
 
NI* 
 
 
- 
Race 
Black 
White 
Asian 
Coloured 
 
762/3404(22.4) 
13/48 (27.1) 
5/18 (27.8) 
53/248 (21.4) 
 
1.0 
1.3 (0.68, 2.4) 
1.3 (4.7, 3.8) 
0.94 (0.69, 1.3) 
 
Reference 
0.44 
0.59 
0.71 
 
 
NI 
 
 
- 
Collection year 
2003 
2004 
2005 
 
239/1028(23.3) 
310/1359(22.8) 
291/1349(21.6) 
 
1.0 
0.98 (0.80, 1.2) 
0.91 (0.75, 1.1) 
 
Reference 
0.80 
0.33 
 
 
NI 
 
 
- 
Serotypes 
Non-vaccine 
Vaccine 
 
412/1954(21.1) 
301/1279(23.5) 
 
1.0 
1.2 (0.98, 1.4) 
 
Reference 
0.10 
 
NS** 
 
- 
Province 
Gauteng 
Eastern Cape 
Western Cape 
Mpumalanga 
KwaZulu Natal 
North West 
Free State 
Limpopo 
 
524/2167(24.2) 
18/67 (26.9) 
110/664 (16.6) 
19/62 (31.0) 
106/481 (22.0) 
0 (0.0) 
55/257 (21.4) 
8 /37 (21.6) 
 
1.0 
1.2 (0.67, 2.0) 
0.62(0.49,0.78) 
1.4 (0.80, 2.4) 
0.89 (0.70, 1.1) 
N/A 
0.85 (0.62, 1.2) 
0.86 (0.39, 1.9) 
 
Reference 
0.61 
<0.001 
0.24 
0.32 
- 
0.32 
0.72 
 
1.0 
2.7 (1.7,4.2) 
0.48 (0.33,0.70) 
3.3 (2.1,5.2) 
0.92 (0.62, 1.4) 
N/A 
1.2 (0.81,1.6) 
2.0 (1.1, 3.9) 
 
- 
<0.001 
<0.001 
<0.001 
0.66 
- 
0.42 
0.030 
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Nosocomial infection 
No 
Yes 
 
813/3624(22.4) 
27/112 (24.1) 
 
1.0 
1.1 (0.71, 1.7) 
 
Reference 
0.68 
 
 
NS 
 
 
- 
Current smoker 
No 
Yes 
 
808/3575(22.6) 
32/112 (20.0) 
 
1.0 
0.85(0.57,1.3) 
 
Reference 
0.42 
 
 
NI 
 
 
- 
HIV infection 
No 
Yes 
 
48/284 (16.9) 
414/2062(20.1) 
 
1.0 
1.2 (0.89, 1.7) 
 
Reference 
0.21 
 
 
NI 
 
- 
Alcohol use 
No 
Yes 
 
818/3633(22.5) 
22/103 (21.4) 
 
1.0 
0.93(0.58,1.5) 
 
Reference 
0.78 
 
 
NI 
 
 
- 
Underlying illnesses 
No 
Yes 
 
154/777(19.8) 
373/1572(23.7) 
 
1.0 
1.3 (1.02, 1.6) 
 
Reference 
0.03 
 
 
NS 
 
- 
Pitt bacteraemia score 
<4 
≥4 
 
452/2326(19.4) 
113/185 (61.1) 
 
1.0 
6.3 (4.6, 8.5) 
 
Reference 
<0.001 
 
 
5.5(3.8,7.9) 
 
 
<0.001 
Prior antibiotic use (24h)  
No 
Yes 
 
602/2991(20.0) 
36/144 (25.0) 
 
1.0 
1.3 (0.90, 1.9) 
 
Reference 
0.16 
 
 
NI 
 
 
- 
Prior antibiotic use (2m) 
No 
Yes 
 
303/2004(15.0) 
97/467 (20.8) 
 
1.0 
1.5 (1.1,1.9) 
 
Reference 
0.003 
 
 
1.8(1.3,2.4) 
 
 
<0.001 
Cotrimoxazoleprophylaxis 
No 
Yes 
 
306/1922(15.9) 
111/696 (16.0) 
 
1.0 
(0.79, 1.3) 
 
Reference 
0.99 
 
 
NI 
 
 
- 
Penicillin NonS# 
No 
Yes 
 
494/2302(21.5) 
219/931 (23.5) 
 
1.0 
1.1 (0.93, 1.3) 
 
Reference 
2.0 
 
 
NI 
 
 
- 
Ceftriaxone NonS 
No 
Yes 
 
708/3208(22.1) 
5/25 (20.0) 
 
1.0 
0.88(0.33,2.4) 
 
Reference 
0.80 
 
 
NI 
 
 
- 
Cotrimoxazole NonS 
No 
Yes 
 
277/1296(21.4) 
436/1937(22.5) 
 
1.0 
1.1 (0.90, 1.3) 
 
Reference 
0.44 
 
 
NI 
 
 
- 
Erythromycin NonS 
No 
Yes 
 
600/2798(21.4) 
113/435 (26.0) 
 
1.0 
1.3 (1.02, 1.6) 
 
Reference 
0.03 
 
 
NS 
 
 
- 
NI*: Factors not significant on univariate analysis (P>0.10) were omitted in logistic 
regression model. 
NS**: Factors not significant on multivariate logistic regression analysis  
f 
Number of deaths included only those who died within 30 days of admission 
# NonS: Streptococcus pneumoniae isolates not susceptible to the mentioned 
antibiotics. 
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Analysis of risk factors in meningitis and other invasive pneumococcal disease 
showed that risk factors for death in both groups were similar except for HIV 
infection which was a risk factor in meningitis patients but not in patients with other 
IPD as shown in Tables 3.10 and 3.11. 
 
3.15 Low CD4+ count as a risk factor for death in all IPD patients with HIV 
co-infection (Table 3.12) 
3.15.1 Univariate analysis 
The following factors were significant risk factors for death on univariate analysis 
and were included in the multivariable logistic regression model:  
 Demographic factors: age and province. 
 Microbiologic factors: erythromycin resistance. 
 Clinical factors: Low CD4+ count, Pitt bacteraemia score, prior antibiotic 
use within 2 months before first positive blood /CSF culture, prior antibiotic 
use 24 hours before first positive blood /CSF culture.  
 
3.15.2 Multivariate analysis  
Factors significantly associated with mortality in multivariate analysis.  
3.15.2.1 Demographic factors:  
• Age: Children less than 1 year of age and adults ≥45 years with HIV 
infection were more likely to die compared to other age groups even though 
there was no statistically significant difference. 
 
3.15.2.2 Clinical factors: 
• Pitt bacteraemia score: HIV co-infected patients who were admitted to 
hospital with Pitt bacteraemia score ≥4 had 3.4 times the risk of dying (OR 
3.4, CI 1.5 – 7.9, P=0.004. 
• Meningitis: Meningitis patients with HIV co-infection had 4.5 times the risk 
of dying compared to those with other invasive pneumococcal disease (OR 
4.5, CI 2.4 – 8.5, P=<0.001). 
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• CD4+ count: Patients were 3.7 times more likely to die if their CD4+ count 
was low (OR 3.7, CI 1.5 – 8.7, P=<0.004). 
• Prior antibiotic use within 2 months before first positive blood /CSF culture 
(OR 1.9, CI 0.92 – 3.9, P=0.085) and erythromycin (OR 1.4, CI 0.62 – 2.9, 
P=0.44) were not significantly associated with death. 
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Table 3.12: Univariate and multivariate analysis to assess CD4+ count as a risk 
factor for mortality in HIV-positive patients with invasive pneumococcal 
disease 
 
 
 
 
Univariate analysis 
 
Multivariate analysis 
 
Risk Factor 
 
Case Fatality 
Rate (%) 
 
OR (95% CI) 
Unadjusted 
 
P 
 
OR (95% CI) 
Adjusted 
 
P 
Age group  
<1 
1-4 
5-14 
15-24 
25-44 
45-64 
≥65 
 
124/393 (31.6) 
84 /488 (17.2) 
40/235 (17.0) 
34/145 (23.5) 
285/1061(26.9) 
83/235 (35.3) 
6/17 (35.3) 
 
1.0 
0.45(0.33, 0.62) 
0.44(0.30, 0.66) 
0.66(0.43,1.03) 
0.79(0.62,1.03) 
1.290.84, 1.7) 
1.2(0.43, 3.3) 
 
Reference 
<0.001 
<0.001 
0.068 
0.078 
0.33 
0.75 
 
1.0 
0.34(0.11,1.0) 
0.71(0.19,2.6) 
0.17(0.02,1.5) 
0.87(0.36,2.1) 
1.3(0.39,3.9) 
3.2(0.28,38.4) 
 
Reference 
0.053 
0.60 
0.11 
0.76 
0.70 
0.35 
Sex 
Male 
Female 
 
307/1235 (24.9) 
350/1339 (26.1) 
 
1.0 
1.1(0.89, 1.3) 
 
Reference 
0.46 
 
NI* 
 
- 
Serotypes 
Non-vaccine 
Vaccine 
 
334/1297 (25.8) 
245/956 (25.6) 
 
1.0 
0.99(0.82,1.2) 
 
Reference 
0.95 
 
NI* 
 
- 
Specimen site 
Other IPD 
CSF 
 
416/2065 (20.2) 
241/512 (47.0) 
 
1.0 
3.5 (2.9, 4.3) 
 
Reference 
<0.001 
 
1.0 
4.5 (2.4, 8.5) 
 
Reference 
<0.001 
CD4+ 
Normal 
Low 
 
30/266 (11.3) 
159/683 (23.3) 
 
1.0 
2.4 (1.6,3.6) 
 
Reference 
<0.001 
 
1.0 
3.7 (1.5, 8.7) 
 
Reference 
0.004 
Province 
Gauteng 
Eastern Cape 
Western Cape 
Mpumalanga 
KwaZuluNatal 
North West 
Free State 
Limpopo 
 
448/1664 (26.9) 
40/95 (42.1) 
30/301(10.0) 
21/56 (37.5) 
61/230 (26.5) 
3/4 (75.0) 
51/205 (24.9) 
3/22 (13.6) 
 
1.0 
1.9 (1.3, 3.0) 
0.30(0.20, 0.44) 
1.6 (0.94, 2.8) 
0.98(0.72, 1.3) 
8.1(0.84, 78.4) 
0.90(0.64, 1.3) 
0.43(0.12, 1.5) 
 
Reference 
0.002 
<0.001 
0.083 
0.90 
0.070 
0.53 
0.17 
 
NS* 
 
- 
Nosocomial 
infection 
No 
Yes 
 
 
639/2514 (25.4) 
18/63(28.6) 
 
 
1.0 
1.2 (0.67,2.0) 
 
 
Reference 
0.57 
 
 
NI 
 
 
- 
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Current smoker 
No 
Yes  
 
637/2486 (25.6) 
20/91 (22.0) 
 
1.0 
0.82(0.49,1.4) 
 
Reference 
0.43 
 
NI 
 
- 
Alcohol use 
No 
Yes  
 
639/2507 (25.5) 
18/70 (25.7) 
 
1.0 
1.0(0.59, 1.7) 
 
Reference 
0.97 
 
NI 
 
- 
Underlying illnesses  
No 
Yes 
 
145/586 (24.7) 
274/1107 (24.8) 
 
1.0 
1.0 (0.79,1.3) 
 
Reference 
0.99 
 
NI 
 
- 
Pitt bacteraemia score 
<4 
≥4  
 
388/1683 (23.0) 
86/140 (61.4) 
 
1.0 
5.3 (3.7, 7.6) 
 
Reference 
<0.001 
 
1.0 
3.4 (1.5,7.9) 
 
Reference 
0.004 
Prior antibiotic use (24 
hours) 
No 
Yes  
 
 
499/2122 (23.5) 
34/111 (30.6) 
 
 
1.0 
1.4 (0.95, 2.2) 
 
 
Reference 
0.088 
 
 
NS** 
 
 
- 
Prior antibiotic use (2 
months) 
No 
Yes  
 
 
274/1433 (19.1) 
93/396 (23.5) 
 
 
1.0 
1.3 (0.99, 1.7) 
 
 
Reference 
0.055 
 
 
1.0 
1.9(0.92,3.9) 
 
 
Reference 
0.085 
Cotrimoxazole 
prophylaxis 
No 
Yes  
 
 
219/1169 (18.7) 
147/737 (20.0) 
 
 
1.0 
1.1 (0.86, 1.4) 
 
 
Reference 
0.51 
 
 
NI 
 
 
- 
Penicillin NonS# 
No 
Yes 
 
389/1532 (25.4) 
191/722 (26.5) 
 
1.0 
1.1 (0.86, 1.3) 
 
Reference 
0.59 
 
NI 
 
- 
Ceftriaxone NonS 
No 
Yes 
 
577/2237 (25.8) 
3/17 (17.7) 
 
1.0 
0.62(0.18,2.2) 
 
Reference 
0.45 
 
NI 
 
- 
Cotrimoxazole NonS 
No 
Yes  
 
212/812 (26.1) 
368/1442 (25.5) 
 
1.0 
0.97(0.80,1.2) 
 
Reference 
0.76 
 
NI 
 
- 
Erythromycin NonS 
No 
Yes 
 
478/1907 (25.0) 
102/347 (29.4) 
 
1.0 
1.2(0.97, 1.6) 
 
Reference 
0.090 
 
1.0 
1.4(0.62,2.9) 
 
Reference 
0.44 
 
*NI: Factors not significant on univariate analysis (P>0.10) were omitted in logistic 
regression model. 
**NS: Factors not significant on multivariate logistic regression analysis  
# NonS: Streptococcus pneumoniae isolates not susceptible to the mentioned 
f 
Case Fatality Rate: Number of deaths /Number of patients (%).
 
Number of deaths 
included only those who died within 30 days of admission. 
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3.16 Summary of the results 
The study has shown that age of the patient (<1 year and ≥45 years), province the 
patient lived in (Eastern Cape, Limpopo and Mpumalanga), severity of illness (Pitt 
bacteraemia score ≥4), HIV infection, meningitis and prior antibiotic use within 2 
months before an episode of IPD were statistically significant risk factors associated 
with death in patients with invasive pneumococcal disease. Amongst HIV-positive 
patients severe immunosuppression (low CD4+) was a risk factor for death. Risk 
factors for death were similar in patients with other IPD and meningitis except for 
HIV which was associated with death in the meningitis group but not in the other 
IPD group. Antibiotic resistance and vaccine-serotypes disease were not associated 
with increased risk of death. 
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CHAPTER 4 
 
Discussion  
 
 
4.1 Introduction 
We examined in detail several factors that could possibly predict mortality in 
invasive pneumococcal disease patients in South Africa. The overall mortality of 
28% was not substantially different from the 28% and 30.5% reported from 
previous studies done in the USA and Spain (10;29), however data from Sweden 
documented rates as low as 7% in adults admitted in the late 1970s.(30) Adjusting 
for all potential confounders in a multivariate logistic regression analysis, the 
following factors were significantly associated with mortality: age of the patient (<1 
year and ≥45 years) province the patient lived in (Limpopo and Mpumalanga were 
associated with increased likelihood of dying, while Western Cape was associated 
with decreased likelihood of dying), acute severe illness (Pitt bacteraemia score ≥4), 
HIV infection, meningitis and prior antibiotic use within 2 months before admission 
with an episode of IPD. 
 
Separate analyses of risk factors in the meningitis and other invasive pneumococcal 
disease groups showed that HIV infection was a significant risk factor for death in 
pneumococcal meningitis but not in patients with other invasive pneumococcal 
disease. All other risk factors were the same in both groups and in the overall group 
of patients with IPD. CD4 + count indicative of severe immunosuppression in IPD 
patients with HIV co-infection was a significant risk factor for mortality. Antibiotic 
resistance and vaccine-serotype disease were not associated with mortality. 
 
4.2 Representativeness of the study sample 
The populations included in the multivariate analysis were patients from enhanced 
sites with completed CRFs and available data on outcome. We compared cases 
from enhanced sites to those from non-enhanced to assess whether the population 
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eligible to be included (those from enhanced sites) differed from those at non-
enhanced sites. 
 
There were significant differences in the proportion of cases from these sites, with 
greater proportions of young age reported from enhanced sites. This could be 
because enhanced sites are situated in urban areas where doctors are more likely to 
take blood cultures from young children than in rural areas. The proportion of cases 
by province was also significantly different between enhanced and non-enhanced 
sites. This might be due to the fact that enhanced sites in these provinces are mostly 
in the urban settings, which have bigger hospitals, and dense populations. A greater 
proportion of cases are in this setting in some provinces.  
 
There was significant difference in the proportion of specimens from blood or CSF 
between enhanced and non-enhanced sites. An explanation for this could be that 
clinicians in more rural areas are less likely to do blood cultures. The proportion of 
antibiotic resistance differed between enhanced and non-enhanced sites with greater 
proportions of antibiotics resistance noted in enhanced sites. The reason might be 
due to high utilization of antibiotics in urban settings where the enhanced sites are 
situated compared to non-enhanced sites, which are mostly in rural setting. Such 
differences are consistent with enhanced sites being in larger hospitals in urban 
areas. (Appendix 1) In summary, the population of patients from enhanced sites 
does seem to differ from those from non-enhanced sites in age, antibiotic resistance, 
provincial distribution etc. This may limit generalizability of findings to patients in 
rural areas.  
 
Since our main interest was analysis of IPD outcome, we focused on data from 
enhanced sites with completed case report forms and available data on mortality. 
The reason being mortality data was unreliable in patients without completed CRFs. 
Cases with completed case report forms did not appear to be different from cases 
without case report forms except with regard to proportion of specimens from blood 
or CSF and provincial distribution. Even though our study sample was non-random, 
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it appears homogeneous and relatively representative of all patients admitted to 
enhanced sites. Therefore it is unlikely that the validity of our findings of risk 
factors for death in IPD would be affected. 
 
4.3 Systematic overview of study findings  
 
4.3.1 Meningitis a risk factor for death 
Pneumococcal meningitis was significantly associated with an increased risk of 
dying compared to other invasive disease. A previous study that evaluated risk 
factors associated with mortality did not find meningitis as a significant risk factor 
for death on multivariate analysis.(27)
 
Bacteraemic pneumococcal pneumonia 
constituted 80% of cases of other invasive disease. The case fatality rate for 
meningitis was 45%, which is higher than previously reported rates of 21 -30 % 
from North America and Europe, but lower than 58% which was previously 
reported from South Africa.(2;31-33) In the evaluation of association with mortality 
some studies have excluded meningitis and have mostly looked at the association 
between bacteraemic pneumococcal pneumonia and death.(22;31)
 
 
4.3.2 HIV co-infection as a risk factor for death in pneumococcal meningitis 
Data for HIV was available for 61% of our study sample; of this 87% were HIV co-
infected. Our study found that HIV co-infection did not increase the risk of dying 
with pneumococcal bacteraemia. This is consistent with findings reported from 
previous studies.(10; 31) 
 
However, our study found a significant association 
between HIV co-infection and increased risk of dying with meningitis. This finding 
has not been reported before from other studies. This is an important finding in an 
area where approximately 5.5 million people are living with HIV and where 
antiretroviral treatment (ARV) scaling up program is taking shape.(34) This should 
help clinical decision making in comprehensive care plan for such patients 
including access to antiretroviral treatment. 
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4.3.3 Low CD4+ count a risk factor for death in IPD with HIV co-infection 
To evaluate whether CD4+ count indicative of severe immune deficiency is a 
predictor of mortality we performed an analysis restricted to IPD patients with HIV 
co-infection. We found that those with CD4+ count indicative of severe immune 
deficiency were more likely to die. This finding has not been reported before in 
South Africa. Thus with the antiretroviral (ARV) scale up program we believe that 
allowing this group of patients free access to ARV would substantially improve the 
quality of life and decrease mortality.(22) 
 
4.3.4 Pitt bacteraemia score ≥4 as a predictor of mortality 
The presence of acute severe illness clinically assessed as Pitt bacteraemia score of 
4 and/or higher is a factor that consistently predicts mortality from invasive 
pneumococcal disease. Our stratified analysis by clinical syndrome did not show 
any difference in the association between this factor and mortality. Clinically this 
might be an indicator of an overall picture of overwhelming sepsis. These findings 
are similar to those reported from previous studies.(18;22;25;27) 
 
4.3.5 Risk of death due to IPD differs by province 
Our analysis revealed that the risk of death in patients with IPD differs by province. 
The risk is significantly lower in the Western Cape Province and higher in 
Mpumalanga and Eastern Provinces compared to Gauteng Province. Even after 
stratifying the analysis by clinical syndrome, we obtained similar results. Our data 
could not allow us to find a definitive explanation for this finding. We can however 
suggest that possible differences in health care services available including access 
to care and case management in these provinces lead to differential outcome in 
patients with IPD. Differences in specimen-taking practices may mean that the 
spectrum of patients included differ between provinces e.g. in some provinces only 
very sick patients had blood cultures done. This is a unique finding and has not 
been reported before in South Africa. 
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4.3.6 Prior antibiotic use within 2 months before admission 
Our study found that prior antibiotic use within 2 months before admission was a 
significant risk factor for mortality. This finding has not been reported before. 
Previous studies have used data on prior antibiotic use before a patient was admitted 
to hospital as a marker for antibiotic resistance.(27) Our study did not find an 
association between antibiotic resistance and mortality. However significant 
differences were noted in the proportion of patients who had used antibiotics 2 
months prior to admission with an episode of IPD compared to those who did not 
use antibiotics. Such differences were apparent in the distribution of these factors: 
age, vaccine-serotypes, cotrimoxazole prophylaxis, HIV infection, underlying 
illness and antibiotic resistance such as penicillin, ceftriaxone, cotrimoxazole and 
erythromycin. We do not have a clear understanding of the influence of prior 
antibiotic use on mortality. However our data seems to suggest that such patients 
were more likely to have been HIV-positive children with possible recurrent 
infections due to immunodeficiency (35) and therefore at a higher risk of dying. 
 
4.3.7 Age associated with the risk of death 
Children less than 1 year and adults ≥ 45 years were more likely to die compared to 
other age groups. This is consistent with findings reported from other studies. 
Previous studies have reported a significant association between age ≥65 years and 
death (22;27;31). Reasons for our finding that the 45–64 year old age group were at 
increased risk of dying as compared to other age groups are unclear. The fact that 
those ≥65 years were not at greater risk of dying than the 45-64 year age group 
could be due to differences in population structure with developed countries having 
a bigger population of the elderly who have a higher prevalence of underlying 
illnesses (e.g. cancer) compared to South Africa. 
 
4.3.8 Penicillin non-susceptibility not associated with mortality 
There was no association found between antibiotic non-susceptibility and increased 
risk of mortality in all our models. This finding is consistent with published 
literature of previous studies done in Korea, Spain, Canada, Sweden etc that found 
 63 
no association between resistance to antibiotics such as penicillin and death.(12; 22; 
36) However, we did not assess discordant/concordant therapy among the patients 
as we were limited by available data. 
 
4.3.9 Vaccine–serotype IPD not associated with increased risk of death  
Our study found that vaccine-serotype IPD was not associated with an increased 
risk of death. To our knowledge there is no published literature showing an 
association between vaccine-serotype disease and an increased risk of death. 
 
4.3.10 Underlying illness not associated with mortality 
There was no association seen between underlying illnesses and increased risk of 
death in IPD patients. Studies done in developed countries i.e. the USA, Canada, 
Great Britain etc have shown an association between underlying illness e.g. diabetes 
and mortality.(18;22;27) This might be due to differences in the prevalence of 
chronic diseases between these areas with South Africa experiencing a lower 
prevalence of such disease. We grouped all underlying diseases together for this 
analysis, as numbers of patients were too small to assess each one individually. 
 
4.4 Potential Study Biases 
4.4.1 Collection of exposure and outcome data 
The standard practice in data collection was use of objective data sources e.g. death 
certificates and medical records. However data on antibiotic use before admission 
to hospital was collected through person-to-person interviews. Systematic 
differences might have arisen due to differences in interviewing skills between 
surveillance officers. 
 
4.4.2 Underestimation of incidence rates 
Invasive pneumococcal disease cases captured by the surveillance system might not 
be representative of all the cases of IPD occurring in South Africa within the study 
period. It is not common practice to do blood cultures in all febrile illnesses; hence 
some patients might have been missed. Patients who died at home or in transit to 
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the hospital and those treated for clinical meningitis in cases of failed lumbar 
puncture might also not have been captured by the surveillance system. Therefore 
the incidence rates reported earlier on are certainly an underestimation of the true 
burden of the disease. Thus surveillance bias might exist in our study. 
 
4.4.3 Bias in risk factor analysis  
Underestimation of disease burden might have introduced an erroneous estimation 
of mortality and associated risk factors in our study. Even though missing data are a 
common problem with the surveillance system, our sample populations which were 
cases from enhanced sites with completed case report forms and data on mortality, 
was quite comparable to cases from enhanced sites without case report forms. Use 
of strict case definition for exposure and outcome might have helped to minimize 
information bias. To minimize bias in risk factor analysis we restricted our analysis 
to patients that died within 30 days after admission. 
 
4.5 Residual confounding 
All factors of interest were initially examined in a univariate model to find out if 
they were associated with increased risk of death. Significant factors at P≤0.1 were 
included in the multivariate logistic regression model where each factor controlled 
for the confounding effect of the other. This method helped to control for the 
confounding effect of several factors at the same time. Factors significant at P≤0.05 
were then considered significant risk factors for mortality.  
 
Residual confounding effect in the association between the risk factors identified 
and mortality remains a possibility. We did not examine all factors associated with 
IPD that could also be risk factors for death such as socioeconomic status and 
access to health services. This information was lacking in our database. However 
the strength of the association observed between the identified risk factors and 
mortality might not have been due to chance or residual confounding.(21)  
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4.6 Generalizability 
There appears to be significant differences between cases from enhanced and non-
enhanced sites and our population of interest was cases from enhanced sites. This 
might limit generalizability of our study findings beyond populations of enhanced 
sites. The difference in the distribution of cases by province might limit 
generalizability of our study results to other provinces and more rural areas. In the 
light of the foregoing facts our findings might only be extrapolated to enhanced 
surveillance sites. 
 
4.7 Study Strengths  
• Our study used national data of laboratory-confirmed cases of IPD to 
evaluate and determine risk factors for death in invasive pneumococcal 
disease. 
• The large numbers of cases included in our study gave enough power to 
detect differences in risk factors for mortality that were evaluated. 
 
4.8 Study Limitations   
• Detailed data on severity of illness and other clinical indicators of disease 
severity i.e. mechanical ventilation, Glasgow coma score etc was not 
available as such we could not make an in-depth analysis of clinical risk 
factors associated with mortality. 
• Our study involved retrospective data analysis using surveillance database. 
The data was not collected specifically for this purpose as such some 
parameters of interest were not collected e.g. white blood cell count. 
• We did not have data on mortality post admission as such death due IPD 
might have been underestimated  
• We could not be sure that death was due to IPD, death could have occurred 
due to other conditions. To minimize this we restricted our analysis to death 
that occurred within 30 days after admission. 
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• This was an analysis of an existing dataset hence other than knowing the 
antibiotic the patient received we did not have information on the dosage 
and the duration of treatment as this was not available. Therefore it was 
difficult to establish discordant therapy (when the patient is treated with an 
antibiotic to which the organism is resistant). As such we could not fully 
examine the association between antibiotic resistance and mortality. 
• Data for antibiotic treatment were available only for 2005, and it was 
therefore not possible to compare antibiotic use between the three years and 
assess its effect on mortality accordingly. 
• There was insufficient data on the number of cases that actually were put on 
ARV to make a meaningful analysis. This also applied to cases that had 
viral load results. Analysis of association between CD4+ count and 
mortality for HIV co-infected children was based on absolute counts, as we 
did not have sufficient data on CD4+%, which is a more reliable measure.  
• We also did not have a sufficient number of HIV-positive meningitis cases 
with CD4+ count to make a meaningful analysis of the effect of CD4 count 
on mortality risk in this group. 
 
4.9 Suggestions for further studies.  
In view of the findings discussed in this chapter, further research is needed to 
gain a clear understanding behind the provincial differences in the likelihood of 
dying from IPD. In addition future studies should investigate: 
• The association between mortality and prior antibiotic use within 2 months 
preceding admission with an episode of IPD. 
•  The association between low CD4+ and mortality in HIV-positive patients 
with meningitis  
• Risk factors for early (within 2 days) versus late deaths (after 2 to 30 days) 
to establish if such factors are different.
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CHAPTER 5 
 
Conclusions and Recommendations 
 
5.1 Conclusions 
In conclusion, we found that the case fatality rate for all IPD was 28%. The case 
fatality rate was higher for meningitis (45%) than for other IPD (22.5%). Meningitis 
was significantly associated with death compared to other IPD and that HIV 
infection was a significant risk factor for death in patients with meningitis and not 
in patients with other IPD. Children less than 1 year and adults ≥45 years had a 
higher likelihood of dying compared to other age groups. Province, Pitt bacteraemia 
score ≥4, and prior antibiotic use within 2 months before admission with an episode 
of IPD were independently associated with death. Risk factors were similar between 
meningitis patients and those with other IPD except for HIV infection. CD4+ count 
indicative of severe immunosuppression was a significant risk factor for death in 
HIV co–infected patients. No association was observed between antibiotic 
resistance and vaccine-serotype and the risk of dying. 
 
5.2 Key Points 
• The risk of death from IPD is greater in children less than 1 year and adults ≥45 
years old. 
• The risk of death is greater in patients with meningitis compared to those with 
other IPD. 
• HIV co-infection is a risk factor for death in meningitis and not other invasive 
disease. 
• Low CD4+ count is a significant risk factor for death in HIV co–infected IPD 
patients. 
• Pitt bacteraemia score ≥4 is a significant predictor of mortality in all IPD. 
• The risk of death in patients with IPD differs by province.  
• Prior antibiotic use within 2 months before admission with an episode of IPD is 
a risk factor for death 
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5.3 Summary and Recommendations 
In summary, the study findings of risk factors for mortality in patients with invasive 
pneumococcal disease as outlined above are valid and unlikely to be due to chance, 
sampling bias or residual confounding. Risk factors for death in patients with IPD 
in South Africa have not been examined before on a national level since good 
quality data on laboratory-confirmed IPD were lacking. To our knowledge HIV 
infection as an independent risk factor for death in pneumococcal meningitis has 
not been previously evaluated in a multivariate model. Most studies have focused 
on risk factors for death in bacteraemic pneumococcal pneumonia and HIV 
infection using either retrospective or prospective data.(17;31) 
  
We feel that our study is unique and provides new information to clinicians and 
public health practitioners for the identification of populations at risk of death. 
Clinicians should be aware that while young children particularly under the age of 5 
years have higher incidence rates of IPD, those under the age of 1 year carry the 
greatest risk of death and ought to be managed appropriately to minimize their risk 
of dying. Public health practitioners should therefore reinforce targeted preventive 
health services to this age group. This point drives home the importance of 
considering a pneumococcal conjugate vaccine(13;13;14) for children below the 
age of five years as part of the national expanded program for immunization (EPI), 
and patients with an increased risk of IPD e.g. patients with HIV co-infection. 
 
These findings have broader implications on public health policy and government 
commitment to appropriate health intervention measures such as adequate resource 
allocation to preventive health services, public health education on early 
presentation to a health care facility and enhancement of primary health care 
facilities. 
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Map of South African provinces showing enhanced surveillance sites (green circles) 
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